## Enrico Bertini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2048579/publications.pdf Version: 2024-02-01



ENDICO REDTINI

#	Article	IF	CITATIONS
1	Analysis of glutathione: implication in redox and detoxification. Clinica Chimica Acta, 2003, 333, 19-39.	0.5	931
2	Consensus Statement for Standard of Care in Spinal Muscular Atrophy. Journal of Child Neurology, 2007, 22, 1027-1049.	0.7	754
3	Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nature Genetics, 2012, 44, 1243-1248.	9.4	712
4	An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature, 1989, 339, 309-311.	13.7	640
5	Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nature Genetics, 2009, 41, 829-832.	9.4	610
6	Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nature Genetics, 2006, 38, 910-916.	9.4	592
7	Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 2018, 28, 103-115.	0.3	584
8	Mutations of SURF-1 in Leigh Disease Associated with Cytochrome c Oxidase Deficiency. American Journal of Human Genetics, 1998, 63, 1609-1621.	2.6	504
9	PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nature Genetics, 2006, 38, 752-754.	9.4	497
10	Empirical Studies in Information Visualization: Seven Scenarios. IEEE Transactions on Visualization and Computer Graphics, 2012, 18, 1520-1536.	2.9	429
11	Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders, 2018, 28, 197-207.	0.3	421
12	Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disorders, 2019, 29, 842-856.	0.3	401
13	Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nature Genetics, 2009, 41, 1032-1036.	9.4	383
14	Clinical and Molecular Phenotype of Aicardi-Goutières Syndrome. American Journal of Human Genetics, 2007, 81, 713-725.	2.6	375
15	Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. Nature Genetics, 2006, 38, 623-625.	9.4	368
16	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	6.3	365
17	Spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2011, 6, 71.	1.2	363
18	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	1.0	357

#	Article	IF	CITATIONS
19	Mutations in the gene encoding immunoglobulin μ-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nature Genetics, 2001, 29, 75-77.	9.4	317
20	Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nature Genetics, 2007, 39, 366-372.	9.4	303
21	COQ2 Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 2773-2780.	3.0	297
22	Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurology, The, 2012, 11, 443-452.	4.9	297
23	Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7516-7521.	3.3	288
24	Diagnostic approach to the congenital muscular dystrophies. Neuromuscular Disorders, 2014, 24, 289-311.	0.3	275
25	THE 6â€minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle and Nerve, 2013, 48, 343-356.	1.0	258
26	De novo <i>LMNA</i> mutations cause a new form of congenital muscular dystrophy. Annals of Neurology, 2008, 64, 177-186.	2.8	255
27	Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy Is Caused by Mutations in ASAH1. American Journal of Human Genetics, 2012, 91, 5-14.	2.6	250
28	miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Molecular Medicine, 2011, 3, 258-265.	3.3	242
29	Spectrum of <i>SCN1A</i> mutations in severe myoclonic epilepsy of infancy. Neurology, 2003, 60, 1961-1967.	1.5	241
30	The 6â€minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle and Nerve, 2013, 48, 357-368.	1.0	240
31	The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability. Neuromuscular Disorders, 2010, 20, 155-161.	0.3	239
32	Approach to the diagnosis of congenital myopathies. Neuromuscular Disorders, 2014, 24, 97-116.	0.3	239
33	Neurodegeneration associated with genetic defects in phospholipase A <sub>2</sub> . Neurology, 2008, 71, 1402-1409.	1.5	236
34	Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. European Journal of Human Genetics, 2004, 12, 59-65.	1.4	235
35	Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy. Nature Genetics, 2013, 45, 83-87.	9.4	231
36	<i>RYR1</i> mutations are a common cause of congenital myopathies with central nuclei. Annals of Neurology, 2010, 68, 717-726.	2.8	230

#	Article	IF	CITATIONS
37	Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB Journal, 2007, 21, 1210-1226.	0.2	209
38	Infantile-Onset Ascending Hereditary Spastic Paralysis Is Associated with Mutations in the Alsin Gene. American Journal of Human Genetics, 2002, 71, 518-527.	2.6	203
39	Consensus Statement on Standard of Care for Congenital Muscular Dystrophies. Journal of Child Neurology, 2010, 25, 1559-1581.	0.7	200
40	Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of α-Dystroglycan. American Journal of Human Genetics, 2013, 93, 29-41.	2.6	197
41	Cerebellar ataxia and coenzyme Q10 deficiency. Neurology, 2003, 60, 1206-1208.	1.5	195
42	Quality Metrics in High-Dimensional Data Visualization: An Overview and Systematization. IEEE Transactions on Visualization and Computer Graphics, 2011, 17, 2203-2212.	2.9	189
43	Leukoencephalopathy with thalamus and brainstem involvement and high lactate â€~LTBL' caused by EARS2 mutations. Brain, 2012, 135, 1387-1394.	3.7	187
44	Mutations in KLHL40 Are a Frequent Cause of Severe Autosomal-Recessive Nemaline Myopathy. American Journal of Human Genetics, 2013, 93, 6-18.	2.6	186
45	SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain, 2007, 130, 862-874.	3.7	180
46	Impaired Skin Fibroblast Carnitine Uptake in Primary Systemic Carnitine Deficiency Manifested by Childhood Carnitine-Responsive Cardiomyopathy. Pediatric Research, 1990, 28, 247-255.	1.1	179
47	Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscular Disorders, 2009, 19, 458-461.	0.3	171
48	North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2010, 20, 712-716.	0.3	171
49	Phosphomannose Isomerase Deficiency: A Carbohydrate-Deficient Glycoprotein Syndrome with Hepatic-Intestinal Presentation. American Journal of Human Genetics, 1998, 62, 1535-1539.	2.6	167
50	Congenital muscular dystrophies with defective glycosylation of dystroglycan. Neurology, 2009, 72, 1802-1809.	1.5	166
51	EPI-743 reverses the progression of the pediatric mitochondrial disease—Genetically defined Leigh Syndrome. Molecular Genetics and Metabolism, 2012, 107, 383-388.	0.5	163
52	Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain, 2007, 130, 2024-2036.	3.7	161
53	Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology, 2007, 68, 51-55.	1.5	159
54	Homozygosity mapping of Hallervorden–Spatz syndrome to chromosome 20p12.3–p13. Nature Genetics, 1996, 14, 479-481.	9.4	158

#	Article	IF	CITATIONS
55	Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF―mutation. Neurology, 2013, 80, 2049-2054.	1.5	157
56	Clutathione in blood of patients with Friedreich's ataxia. European Journal of Clinical Investigation, 2001, 31, 1007-1011.	1.7	154
57	Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology, 2007, 68, 1782-1789.	1.5	154
58	Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy. Journal of Clinical Investigation, 2014, 124, 4693-4708.	3.9	153
59	The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology, 2004, 62, 1509-1517.	1.5	152
60	Functional changes in Duchenne muscular dystrophy. Neurology, 2011, 77, 250-256.	1.5	151
61	Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. European Journal of Human Genetics, 2005, 13, 256-259.	1.4	148
62	Consensus Statement on Standard of Care for Congenital Myopathies. Journal of Child Neurology, 2012, 27, 363-382.	0.7	147
63	Infantile Alexander Disease: Spectrum of GFAP Mutations and Genotype-Phenotype Correlation. American Journal of Human Genetics, 2001, 69, 1134-1140.	2.6	146
64	Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 643-649.	0.3	144
65	Actin Glutathionylation Increases in Fibroblasts of Patients with Friedreich's Ataxia. Journal of Biological Chemistry, 2003, 278, 42588-42595.	1.6	142
66	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders, 2016, 26, 126-131.	0.3	142
67	Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Annals of Neurology, 2003, 54, 719-724.	2.8	141
68	Hemimegalencephaly and Intractable Epilepsy: Benefits of Hemispherectomy. Epilepsia, 1989, 30, 833-843.	2.6	139
69	CEP290 Mutations Are Frequently Identified in the Oculo-Renal Form of Joubert Syndrome–Related Disorders. American Journal of Human Genetics, 2007, 81, 104-113.	2.6	137
70	Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain, 2008, 131, 747-759.	3.7	134
71	Hypomyelinating leukodystrophies: Translational research progress and prospects. Annals of Neurology, 2014, 76, 5-19.	2.8	132
72	MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain, 2013, 136, 872-881.	3.7	130

#	Article	IF	CITATIONS
73	INFUSE: Interactive Feature Selection for Predictive Modeling of High Dimensional Data. IEEE Transactions on Visualization and Computer Graphics, 2014, 20, 1614-1623.	2.9	129
74	Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscular Disorders, 2004, 14, 130-135.	0.3	128
75	CloudLines: Compact Display of Event Episodes in Multiple Time-Series. IEEE Transactions on Visualization and Computer Graphics, 2011, 17, 2432-2439.	2.9	127
76	AHI1gene mutations cause specific forms of Joubert syndrome-related disorders. Annals of Neurology, 2006, 59, 527-534.	2.8	125
77	GPR56-related bilateral frontoparietal polymicrogyria: further evidence for an overlap with the cobblestone complex. Brain, 2010, 133, 3194-3209.	3.7	125
78	Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Movement Disorders, 2011, 26, 1755-1759.	2.2	125
79	Fatal infantile liver failure associated with mitochondrial DNA depletion. Journal of Pediatrics, 1992, 121, 896-901.	0.9	123
80	Mutations in GTPBP3 Cause a Mitochondrial Translation Defect Associated with Hypertrophic Cardiomyopathy, Lactic Acidosis, and Encephalopathy. American Journal of Human Genetics, 2014, 95, 708-720.	2.6	123
81	DPM2â€CDG: A muscular dystrophy–dystroglycanopathy syndrome with severe epilepsy. Annals of Neurology, 2012, 72, 550-558.	2.8	121
82	Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation. Journal of Pediatrics, 2012, 161, 705-709.e1.	0.9	121
83	Phenotypic clustering of lamin A/C mutations in neuromuscular patients. Neurology, 2007, 69, 1285-1292.	1.5	120
84	Dominantly inherited mitochondrial myopathy with multiple deletions of mitochondrial DNA. Neurology, 1991, 41, 1053-1053.	1.5	120
85	The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender?. Journal of Neurology, 2014, 261, 504-510.	1.8	119
86	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. Journal of Bone and Mineral Research, 2011, 26, 1891-1903.	3.1	116
87	Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biology, 2001, 20, 475-486.	1.5	115
88	GM1 gangliosidosis and Morquio B disease: An update on genetic alterations and clinical findings. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 782-790.	1.8	115
89	Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Human Mutation, 2012, 33, 949-959.	1.1	115
90	Mutations in the MTM1 gene implicated in X-linked myotubular myopathy. ENMC International Consortium on Myotubular Myopathy. European Neuro- Muscular Center. Human Molecular Genetics, 1997, 6, 1505-1511.	1.4	113

#	Article	IF	CITATIONS
91	Mutation of plasma membrane Ca <sup>2+</sup> ATPase isoform 3 in a family with X-linked congenital cerebellar ataxia impairs Ca <sup>2+</sup> homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14514-14519.	3.3	113
92	Multi-minicore disease-searching for boundaries: Phenotype analysis of 38 cases. Annals of Neurology, 2000, 48, 745-757.	2.8	112
93	Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology, 2009, 72, 784-792.	1.5	110
94	Clinical features, risk factors, and prognosis in transient global amnesia: a follow-up study. European Journal of Neurology, 2005, 12, 350-356.	1.7	109
95	Renal involvement in mitochondrial cytopathies. Pediatric Nephrology, 2012, 27, 539-550.	0.9	109
96	The expanding phenotype ofPOMT1mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation. Human Mutation, 2006, 27, 453-459.	1.1	106
97	Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations. Molecular Genetics and Metabolism, 2012, 105, 463-471.	0.5	106
98	Affinity proteomics within rare diseases: a <scp>BIO</scp> â€ <scp>NMD</scp> study for blood biomarkers of muscular dystrophies. EMBO Molecular Medicine, 2014, 6, 918-936.	3.3	105
99	Distinguishing the four genetic causes of jouberts syndrome-related disorders. Annals of Neurology, 2005, 57, 513-519.	2.8	104
100	Characterization of recessive RYR1 mutations in core myopathies. Human Molecular Genetics, 2006, 15, 2791-2803.	1.4	103
101	Somatic and germline mosaicisms in Severe Myoclonic Epilepsy of Infancy. Biochemical and Biophysical Research Communications, 2006, 341, 489-493.	1.0	102
102	Autophagy regulates satellite cell ability to regenerate normal and dystrophic muscles. Cell Death and Differentiation, 2016, 23, 1839-1849.	5.0	102
103	A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, 4-15.	0.3	102
104	24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2013, 8, e52512.	1.1	99
105	Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. PLoS ONE, 2014, 9, e108205.	1.1	98
106	The inv dup(15) syndrome. Neurology, 1997, 48, 1081-1086.	1.5	97
107	Daily salbutamol in young patients with SMA type II. Neuromuscular Disorders, 2008, 18, 536-540.	0.3	97
108	Agenesis of the corpus callosum, combined immunodeficiency, bilateral cataract, and hypopigmentation in two brothers. American Journal of Medical Genetics Part A, 1988, 29, 1-8.	2.4	96

#	Article	IF	CITATIONS
109	<i>MKS3/TMEM67</i> mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement. Human Mutation, 2009, 30, E432-E442.	1.1	96
110	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522.	4.9	95
111	Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscular Disorders, 2021, 31, 574-582.	0.3	94
112	NPHP1 gene deletion is a rare cause of Joubert syndrome related disorders. Journal of Medical Genetics, 2005, 42, e9-e9.	1.5	93
113	Oligophrenin 1 mutations frequently cause X-linked mental retardation with cerebellar hypoplasia. Neurology, 2005, 65, 1364-1369.	1.5	93
114	Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscular Disorders, 2008, 18, 389-393.	0.3	92
115	Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations in <i>TPM2</i> and <i>TPM3</i> Causing Congenital Myopathies. Human Mutation, 2014, 35, 779-790.	1.1	92
116	The genetic basis of undiagnosed muscular dystrophies and myopathies. Neurology, 2016, 87, 71-76.	1.5	92
117	Description, Nomenclature, and Mapping of a Novel Cerebello-Renal Syndrome with the Molar Tooth Malformation. American Journal of Human Genetics, 2003, 73, 663-670.	2.6	91
118	Congenital Muscular Dystrophies: A Brief Review. Seminars in Pediatric Neurology, 2011, 18, 277-288.	1.0	91
119	Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. Neuromuscular Disorders, 2010, 20, 438-442.	0.3	90
120	Disease-Causing SDHAF1 Mutations Impair Transfer of Fe-S Clusters to SDHB. Cell Metabolism, 2016, 23, 292-302.	7.2	89
121	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52.	4.9	89
122	Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. European Journal of Human Genetics, 2004, 12, 561-566.	1.4	87
123	Cerebroretinal microangiopathy with calcifications and cysts (CRMCC). American Journal of Medical Genetics, Part A, 2008, 146A, 182-190.	0.7	87
124	Role of Gabapentin in Spinal Muscular Atrophy. Journal of Child Neurology, 2003, 18, 537-541.	0.7	86
125	COQ4 Mutations Cause a Broad Spectrum of Mitochondrial Disorders Associated with CoQ10 Deficiency. American Journal of Human Genetics, 2015, 96, 309-317.	2.6	86
126	Natural history of pulmonary function in collagen VI-related myopathies. Brain, 2013, 136, 3625-3633.	3.7	85

#	Article	IF	CITATIONS
127	POPDC1S201F causes muscular dystrophy and arrhythmia by affecting protein trafficking. Journal of Clinical Investigation, 2015, 126, 239-253.	3.9	85
128	Evaluation of alternative glyph designs for time series data in a small multiple setting. , 2013, , .		84
129	Fatal hypertrophic cardiomyopathy and nemaline myopathy associated with ACTA1 K336E mutation. Neuromuscular Disorders, 2006, 16, 548-552.	0.3	83
130	Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient. Orphanet Journal of Rare Diseases, 2012, 7, 18.	1.2	83
131	Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 201-206.	0.3	83
132	Nusinersen in type 1 spinal muscular atrophy: Twelveâ€month realâ€world data. Annals of Neurology, 2019, 86, 443-451.	2.8	83
133	Clinical and genetic studies in hereditary spastic paraplegia with thin corpus callosum. Neurology, 2004, 62, 262-268.	1.5	82
134	Motor function-muscle strength relationship in spinal muscular atrophy. Muscle and Nerve, 2004, 29, 548-552.	1.0	81
135	Importance of <i>SPP1</i> genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.5	81
136	Congenital myopathies: clinical phenotypes and new diagnostic tools. Italian Journal of Pediatrics, 2017, 43, 101.	1.0	80
137	The T9176G mtDNA mutation severely affects ATP production and results in Leigh syndrome. Neurology, 2001, 56, 687-690.	1.5	79
138	Succinate oA ligase deficiency due to mutations in <i>SUCLA2</i> and <i>SUCLG1</i> : phenotype and genotype correlations in 71 patients. Journal of Inherited Metabolic Disease, 2016, 39, 243-252.	1.7	79
139	Cardiomyopathy may be the only clinical manifestation in female carriers of Duchenne muscular dystrophy. Neurology, 1993, 43, 2342-2342.	1.5	79
140	Collagen type VI and related disorders: Bethlem myopathy and Ullrich scleroatonic muscular dystrophy. European Journal of Paediatric Neurology, 2002, 6, 193-198.	0.7	77
141	Novel <i>TMEM67</i> mutations and genotype-phenotype correlates in meckelin-related ciliopathies. Human Mutation, 2010, 31, n/a-n/a.	1.1	77
142	Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 695-706.	5.5	77
143	Subcomplexes of human ATP synthase mark mitochondrial biosynthesis disorders. Annals of Neurology, 2006, 59, 265-275.	2.8	75
144	Friedreich's ataxia: Oxidative stress and cytoskeletal abnormalities. Journal of the Neurological Sciences, 2009, 287, 111-118.	0.3	75

#	Article	IF	CITATIONS
145	Joubert syndrome and related disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1879-1888.	1.0	75
146	Frataxin Deficiency Leads to Reduced Expression and Impaired Translocation of NF-E2-Related Factor (Nrf2) in Cultured Motor Neurons. International Journal of Molecular Sciences, 2013, 14, 7853-7865.	1.8	75
147	Prevalence of congenital muscular dystrophy in Italy. Neurology, 2015, 84, 904-911.	1.5	75
148	Progressive neuropathy and recurrent myoglobinuria in a child with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Journal of Pediatrics, 1991, 118, 744-746.	0.9	74
149	Spectrum of phenotypes in female patients with epilepsy due to protocadherin 19 mutations. Epilepsia, 2011, 52, 1251-1257.	2.6	74
150	A new syndrome with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts. Journal of Pediatrics, 1994, 124, 79-86.	0.9	73
151	<i>GJA12</i> mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology, 2008, 70, 748-754.	1.5	73
152	Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. Annals of Neurology, 2005, 58, 400-410.	2.8	72
153	Clinical and genetic characterization of Chanarin–Dorfman syndrome. Biochemical and Biophysical Research Communications, 2008, 369, 1125-1128.	1.0	72
154	Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 16041-16046.	3.3	71
155	Assessing upper limb function in nonambulant SMA patients: Development of a new module. Neuromuscular Disorders, 2011, 21, 406-412.	0.3	71
156	Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway. Human Molecular Genetics, 2017, 26, 2781-2790.	1.4	71
157	Pontocerebellar hypoplasia type 6 caused by mutations in <i>RARS2</i> : definition of the clinical spectrum and molecular findings in five patients. Journal of Inherited Metabolic Disease, 2013, 36, 43-53.	1.7	70
158	MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet Journal of Rare Diseases, 2016, 11, 91.	1.2	70
159	New clinical phenotype of branched-chain acyl-CoA oxidation defect. Lancet, The, 1991, 338, 1522-1523.	6.3	69
160	Mutation analysis in 16 patients with mtDNA depletion. Human Mutation, 2003, 21, 453-454.	1.1	69
161	Genetic heterogeneity of megalencephalic leukoencephalopathy and subcortical cysts. Neurology, 2003, 61, 534-537.	1.5	68
162	Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis. Clinica Chimica Acta, 2005, 355, 105-111.	0.5	68

#	Article	IF	CITATIONS
163	Redefining phenotypes associated with mitochondrial DNA single deletion. Journal of Neurology, 2015, 262, 1301-1309.	1.8	68
164	A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to <i>EIF21B5</i> mutation. Neurology, 2002, 59, 1966-1968.	1.5	67
165	Dominant LMNA mutations can cause combined muscular dystrophy and peripheral neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1019-1021.	0.9	67
166	Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. Neuromuscular Disorders, 2018, 28, 582-585.	0.3	67
167	Fulminant Leigh syndrome and sudden unexpected death in a family with the T9176C mutation of the mitochondrial ATPase 6 gene. Journal of Inherited Metabolic Disease, 1998, 21, 2-8.	1.7	66
168	Novel <i>SACS</i> mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay type. Neurology, 2004, 62, 103-106.	1.5	66
169	Biallelic Mutations in TBCD , Encoding the Tubulin Folding Cofactor D, Perturb Microtubule Dynamics and Cause Early-Onset Encephalopathy. American Journal of Human Genetics, 2016, 99, 962-973.	2.6	66
170	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. Movement Disorders, 2020, 35, 180-184.	2.2	66
171	Megalencephalic leukoencephalopathy with subcortical cysts protein 1 functionally cooperates with the TRPV4 cation channel to activate the response of astrocytes to osmotic stress: dysregulation by pathological mutations. Human Molecular Genetics, 2012, 21, 2166-2180.	1.4	65
172	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. PLoS ONE, 2014, 9, e83400.	1.1	65
173	The hyperornithinemia–hyperammonemia-homocitrullinuria syndrome. Orphanet Journal of Rare Diseases, 2015, 10, 29.	1.2	65
174	SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder. Journal of Clinical Investigation, 2019, 130, 108-125.	3.9	65
175	Fatal infantile leukodystrophy. Neurology, 2001, 57, 265-270.	1.5	64
176	Infantile ascending hereditary spastic paralysis (IAHSP). Neurology, 2003, 60, 674-682.	1.5	64
177	Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscular Disorders, 2006, 16, 93-98.	0.3	64
178	<i>RPGRIP1L</i> mutations are mainly associated with the cerebelloâ€renal phenotype of Joubert syndromeâ€related disorders. Clinical Genetics, 2008, 74, 164-170.	1.0	64
179	Delineation and Diagnostic Criteria of Oral-Facial-Digital Syndrome Type VI. Orphanet Journal of Rare Diseases, 2012, 7, 4.	1.2	64
180	Phenotypic spectrum and prevalence of INPP5E mutations in Joubert Syndrome and related disorders. European Journal of Human Genetics, 2013, 21, 1074-1078.	1.4	64

#	Article	IF	CITATIONS
181	Mutations in APOPT1, Encoding a Mitochondrial Protein, Cause Cavitating Leukoencephalopathy with Cytochrome c Oxidase Deficiency. American Journal of Human Genetics, 2014, 95, 315-325.	2.6	64
182	Functional genome-wide siRNA screen identifies KIAA0586 as mutated in Joubert syndrome. ELife, 2015, 4, e06602.	2.8	64
183	Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. Parkinsonism and Related Disorders, 2019, 61, 19-25.	1.1	64
184	Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype. BMC Medical Genetics, 2012, 13, 73.	2.1	63
185	Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscular Disorders, 2013, 23, 451-455.	0.3	63
186	Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade. EBioMedicine, 2015, 2, 285-293.	2.7	63
187	Microtubule Dysfunction: A Common Feature of Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 7354.	1.8	63
188	Hypoparathyroidism in mitochondrial trifunctional protein deficiency. Journal of Pediatrics, 1996, 129, 159-162.	0.9	62
189	Clinical and molecular findings in patients with giant axonal neuropathy (GAN). Neurology, 2004, 62, 13-16.	1.5	62
190	A new simple and rapid LC–ESI-MS/MS method for quantification of plasma oxysterols as dimethylaminobutyrate esters. Its successful use for the diagnosis of Niemann–Pick type C disease. Clinica Chimica Acta, 2014, 437, 93-100.	0.5	62
191	Effects on Collagen VI mRNA Stability and Microfibrillar Assembly of Three COL6A2Mutations in Two Families with Ullrich Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2002, 277, 43557-43564.	1.6	61
192	Two patients with †Dropped head syndrome' due to mutations in LMNA or SEPN1 genes. Neuromuscular Disorders, 2005, 15, 521-524.	0.3	61
193	Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. Journal of Medical Genetics, 2010, 47, 856-858.	1.5	61
194	Peripheral neuropathy with giant axons and cardiomyopathy associated with desmin type intermediate filaments in skeletal muscle. Journal of the Neurological Sciences, 1992, 109, 1-10.	0.3	60
195	Duchenne muscular dystrophy and epilepsy. Neuromuscular Disorders, 2013, 23, 313-315.	0.3	60
196	Antioxidant enzymes in blood of patients with Friedreich's ataxia. Archives of Disease in Childhood, 2002, 86, 376-379.	1.0	59
197	Mutations in MFSD8/CLN7 are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis. Human Mutation, 2009, 30, E530-E540.	1.1	59
198	Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS ONE, 2019, 14, e0214250.	1.1	59

#	Article	IF	CITATIONS
199	Experience on Therapy of Adrenoleukodystrophy and Adrenomyeloneuropathy. Developmental Neuroscience, 1991, 13, 274-279.	1.0	58
200	International Workshop:. Neuromuscular Disorders, 2017, 27, 1126-1137.	0.3	58
201	Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich's Ataxia. International Journal of Molecular Sciences, 2017, 18, 2173.	1.8	58
202	Peripheral sensory-motor polyneuropathy, pigmentary retinopathy, and fatal cardiomyopathy in long-chain 3-hydroxy-acyl-CoA dehydrogenase deficiency. European Journal of Pediatrics, 1992, 151, 121-126.	1.3	57
203	<i>LMNA</i> -associated myopathies. Neurology, 2014, 83, 1634-1644.	1.5	57
204	<i><scp>PCDH</scp>19</i> â€related epilepsy in two mosaic male patients. Epilepsia, 2016, 57, e51-5.	2.6	57
205	Distal infantile spinal muscular atrophy associated with paralysis of the diaphragm: A variant of infantile spinal muscular atrophy. American Journal of Medical Genetics Part A, 1989, 33, 328-335.	2.4	56
206	Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Neurology, 2001, 57, 911-914.	1.5	56
207	Glutathione metabolism and antioxidant enzymes in children with down syndrome. Journal of Pediatrics, 2003, 142, 583-585.	0.9	56
208	Childhood onset tubular aggregate myopathy associated with de novo STIM1 mutations. Journal of Neurology, 2014, 261, 870-876.	1.8	56
209	Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review. European Journal of Paediatric Neurology, 2015, 19, 497-503.	0.7	56
210	Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Annals of Neurology, 2003, 53, 354-365.	2.8	55
211	MRI in sarcoglycanopathies: a large international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 72-77.	0.9	55
212	244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands. Neuromuscular Disorders, 2020, 30, 93-103.	0.3	55
213	Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. Orphanet Journal of Rare Diseases, 2015, 10, 22.	1.2	54
214	Screening of ARHSP-TCC patients expands the spectrum of <i>SPG11</i> mutations and includes a large scale gene deletion. Human Mutation, 2009, 30, E500-E519.	1.1	53
215	Centronuclear myopathy related to dynamin 2 mutations: Clinical, morphological, muscle imaging and genetic features of an Italian cohort. Neuromuscular Disorders, 2013, 23, 229-238.	0.3	53
216	Detection of common and private mutations in the COL6A1 gene of patients with Bethlem myopathy. Neurology, 2005, 64, 1931-1937.	1.5	52

#	Article	IF	CITATIONS
217	Expanding the clinical spectrum of POMT1 phenotype. Neurology, 2006, 66, 1564-1567.	1.5	52
218	Immunodeficiency in Vici syndrome: A heterogeneous phenotype. American Journal of Medical Genetics, Part A, 2012, 158A, 434-439.	0.7	52
219	Mitochondrial dysfunction in central nervous system white matter disorders. Clia, 2014, 62, 1878-1894.	2.5	52
220	The impact of next-generation sequencing on the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype correlations for rare HSP-related genes. Neurogenetics, 2018, 19, 111-121.	0.7	52
221	Clinicoâ€Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp> â€Ataxia: A Multicenter Study of 59 Patients. Annals of Neurology, 2020, 88, 251-263.	2.8	52
222	Neuromyopathy and restrictive cardiomyopathy with accumulation of intermediate filaments: a clinical, morphological and biochemical study. Acta Neuropathologica, 1991, 81, 632-640.	3.9	51
223	A Heterozygous Splice Site Mutation in COL6A1 Leading to an In-Frame Deletion of the α1(VI) Collagen Chain in an Italian Family Affected by Bethlem Myopathy. Biochemical and Biophysical Research Communications, 1999, 258, 802-807.	1.0	51
224	Pontocerebellar hypoplasia. Neurology, 2010, 75, 1459-1464.	1.5	51
225	Cyclosporine A in Ullrich Congenital Muscular Dystrophy: Long-Term Results. Oxidative Medicine and Cellular Longevity, 2011, 2011, 1-10.	1.9	51
226	TMEM70 deficiency: longâ€ŧerm outcome of 48 patients. Journal of Inherited Metabolic Disease, 2015, 38, 417-426.	1.7	51
227	Centronuclear myopathies: genotype–phenotype correlation and frequency of defined genetic forms in an Italian cohort. Journal of Neurology, 2015, 262, 1728-1740.	1.8	51
228	<i>LYRM7</i> mutations cause a multifocal cavitating leukoencephalopathy with distinct MRI appearance. Brain, 2016, 139, 782-794.	3.7	51
229	A novel AIFM1 mutation expands the phenotype to an infantile motor neuron disease. European Journal of Human Genetics, 2016, 24, 463-466.	1.4	51
230	Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy TreatedÂwith Nusinersen. Journal of Pediatrics, 2020, 219, 223-228.e4.	0.9	51
231	Protein glutathionylation in human central nervous system: Potential role in redox regulation of neuronal defense against free radicals. Journal of Neuroscience Research, 2006, 83, 256-263.	1.3	50
232	Ataxia, Intellectual Disability, and Ocular Apraxia with Cerebellar Cysts: A New Disease?. Cerebellum, 2014, 13, 79-88.	1.4	50
233	â€~Behr syndrome' with OPA1 compound heterozygote mutations. Brain, 2015, 138, e321-e321.	3.7	50
234	A novel gainâ€ofâ€function mutation in <i>ORAI1</i> causes lateâ€onset tubular aggregate myopathy and congenital miosis. Clinical Genetics, 2017, 91, 780-786.	1.0	50

#	Article	IF	CITATIONS
235	Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 594-605.	5.5	50
236	Glutathione: A redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies. Molecular Genetics and Metabolism, 2013, 109, 208-214.	0.5	49
237	TBCE Mutations Cause Early-Onset Progressive Encephalopathy with Distal Spinal Muscular Atrophy. American Journal of Human Genetics, 2016, 99, 974-983.	2.6	49
238	218th ENMC International Workshop:. Neuromuscular Disorders, 2017, 27, 596-605.	0.3	49
239	Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients. Orphanet Journal of Rare Diseases, 2017, 12, 90.	1.2	49
240	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Frontiers in Genetics, 2020, 11, 131.	1.1	49
241	Familial Occurrence of Febrile Seizures and Epilepsy in Severe Myoclonic Epilepsy of Infancy (SMEI) Patients with SCN1A Mutations. Epilepsia, 2006, 47, 1629-1635.	2.6	48
242	Motor Chip: A Comparative Genomic Hybridization Microarray for Copy-Number Mutations in 245 Neuromuscular Disorders. Clinical Chemistry, 2011, 57, 1584-1596.	1.5	48
243	Astrocytes: Emerging stars in leukodystrophy pathogenesis. Translational Neuroscience, 2013, 4, 144-164.	0.7	48
244	Aberrant Function of the C-Terminal Tail of HIST1H1E Accelerates Cellular Senescence and Causes Premature Aging. American Journal of Human Genetics, 2019, 105, 493-508.	2.6	48
245	A novel de novo mutation in the triple helix of the COL6A3 gene in a two-generation Italian family affected by Bethlem myopathy. A diagnostic approach in the mutations' screening of type VI collagen. Neuromuscular Disorders, 1999, 9, 264-271.	0.3	47
246	The Hammersmith functional score correlates with the SMN2 copy number: A multicentric study. Neuromuscular Disorders, 2007, 17, 400-403.	0.3	47
247	SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. European Journal of Human Genetics, 2010, 18, 52-58.	1.4	47
248	Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE, 2019, 14, e0218683.	1.1	47
249	Noninvasive Ventilation in Children with Spinal Muscular Atrophy Types 1 and 2. American Journal of Physical Medicine and Rehabilitation, 2007, 86, 216-221.	0.7	46
250	Visual quality metrics and human perception. , 2010, , .		46
251	Glutathione metabolism in cobalamin deficiency type C (cblC). Journal of Inherited Metabolic Disease, 2014, 37, 125-129.	1.7	46
252	<i>SPG3A</i> . Neurology, 2002, 59, 2002-2005.	1.5	45

<i>SPG3A</i>. Neurology, 2002, 59, 2002-2005. 252

#	Article	IF	CITATIONS
253	"Bartter-like―phenotype in Kearns–Sayre syndrome. Pediatric Nephrology, 2006, 21, 355-360.	0.9	45
254	Exon 45 Skipping Through U1-snRNA Antisense Molecules Recovers the Dys-nNOS Pathway and Muscle Differentiation in Human DMD Myoblasts. Molecular Therapy, 2012, 20, 2134-2142.	3.7	45
255	Hypomorphic Recessive Variants in SUFU Impair the Sonic Hedgehog Pathway and Cause Joubert Syndrome with Cranio-facial and Skeletal Defects. American Journal of Human Genetics, 2017, 101, 552-563.	2.6	45
256	Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS ONE, 2018, 13, e0199223.	1.1	45
257	Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs. International Journal of Molecular Sciences, 2019, 20, 5211.	1.8	45
258	Investigating and reflecting on the integration of automatic data analysis and visualization in knowledge discovery. SIGKDD Explorations: Newsletter of the Special Interest Group (SIG) on Knowledge Discovery & Data Mining, 2010, 11, 9-18.	3.2	45
259	HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscleâ€resident mesenchymal cells. EMBO Reports, 2020, 21, e50863.	2.0	45
260	Intrafamilial variability in hereditary spastic paraplegia associated with an <i>SPG4</i> gene mutation. Neurology, 2000, 55, 702-705.	1.5	44
261	Novel locus for autosomal dominant pure hereditary spastic paraplegia (SPG19) maps to chromosome 9q33-q34. Annals of Neurology, 2002, 51, 681-685.	2.8	44
262	Pontine tegmental cap dysplasia: developmental and cognitive outcome in three adolescent patients. Orphanet Journal of Rare Diseases, 2011, 6, 36.	1.2	44
263	Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. Neuromuscular Disorders, 2014, 24, 347-352.	0.3	44
264	The cytoskeletal arrangements necessary to neurogenesis. Oncotarget, 2016, 7, 19414-19429.	0.8	44
265	The clinical, histologic, and genotypic spectrum of <i>SEPN1</i> -related myopathy. Neurology, 2020, 95, e1512-e1527.	1.5	44
266	Cardiomyopathy and multicore myopathy with accumulation of intermediate filaments. European Journal of Pediatrics, 1990, 149, 856-858.	1.3	43
267	Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement. Brain, 1997, 120, 1139-1148.	3.7	43
268	Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: another genetic hit in the Mediterranean. Neurogenetics, 2006, 7, 111-117.	0.7	43
269	Spastic paraplegia with thin corpus callosum: description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity. Neurogenetics, 2006, 7, 149-156.	0.7	43
270	Progressive cavitating leukoencephalopathy associated with respiratory chain complex I deficiency and a novel mutation in NDUFS1. Neurogenetics, 2011, 12, 9-17.	0.7	43

#	Article	IF	CITATIONS
271	Clinical, neuroradiological and molecular characterization of cerebellar dysplasia with cysts (Poretti–Boltshauser syndrome). European Journal of Human Genetics, 2016, 24, 1262-1267.	1.4	43
272	Towards Understanding Human Similarity Perception in the Analysis of Large Sets of Scatter Plots. , 2016, , .		43
273	Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2016, 11, e0160195.	1.1	43
274	The natural history of Aicardi-Goutieres syndrome: Follow-up of 11 Italian patients. Neurology, 2005, 64, 1621-1624.	1.5	42
275	POMT2 mutation in a patient with â€~MEB-like' phenotype. Neuromuscular Disorders, 2006, 16, 446-448.	0.3	42
276	Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy. Orphanet Journal of Rare Diseases, 2013, 8, 19.	1.2	42
277	Robotic and clinical evaluation of upper limb motor performance in patients with Friedreich's Ataxia: an observational study. Journal of NeuroEngineering and Rehabilitation, 2015, 12, 41.	2.4	42
278	Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. Neuromuscular Disorders, 2017, 27, 447-451.	0.3	42
279	Diagnosis of â€~possible' mitochondrial disease: an existential crisis. Journal of Medical Genetics, 2019, 56, 123-130.	1.5	42
280	The CFC syndrome—report of the first two cases outside the United States. American Journal of Medical Genetics Part A, 1987, 27, 767-771.	2.4	41
281	Sleep-Disordered Breathing in Spinal Muscular Atrophy Types 1 and 2. American Journal of Physical Medicine and Rehabilitation, 2005, 84, 666-670.	0.7	41
282	Revelation of a Novel <i>CLN5</i> Mutation in Early Juvenile Neuronal Ceroid Lipofuscinosis. Neuropediatrics, 2007, 38, 46-49.	0.3	41
283	Six minute walk test in type III spinal muscular atrophy: A 12month longitudinal study. Neuromuscular Disorders, 2013, 23, 624-628.	0.3	41
284	Effects of levosimendan on mitochondrial function in patients withÂseptic shock: A randomized trial. Biochimie, 2014, 102, 166-173.	1.3	41
285	Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscular Disorders, 2015, 25, 749-753.	0.3	41
286	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	0.6	41
287	Identification and characterization of novel collagen VI non-canonical splicing mutations causing ullrich congenital muscular dystrophy. Human Mutation, 2009, 30, E662-E672.	1.1	40
288	Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. Neurology, 2012, 78, 1309-1314.	1.5	40

#	Article	IF	CITATIONS
289	A novel mutation in the endosomal Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES). Epilepsy Research, 2014, 108, 811-815.	0.8	40
290	Reduced steroidogenesis in patients with <scp>PCDH</scp> 19â€female limited epilepsy. Epilepsia, 2017, 58, e91-e95.	2.6	40
291	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.3	40
292	Nephronophthisis type 1 deletion syndrome with neurological symptoms: Prevalence and significance of the association. Kidney International, 2006, 70, 1342-1347.	2.6	39
293	The use of muscle biopsy in the diagnosis of undefined ataxia with cerebellar atrophy in children. European Journal of Paediatric Neurology, 2012, 16, 248-256.	0.7	39
294	Glutathione imbalance in patients with X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism, 2013, 109, 366-370.	0.5	39
295	In vitro neurogenesis: development and functional implications of iPSC technology. Cellular and Molecular Life Sciences, 2014, 71, 1623-1639.	2.4	39
296	Riboflavin responsive mitochondrial myopathy is a new phenotype of dihydrolipoamide dehydrogenase deficiency. The chaperon-like effect of vitamin B2. Mitochondrion, 2014, 18, 49-57.	1.6	39
297	Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy. Neurology, 2015, 85, 1886-1893.	1.5	39
298	<i>UFM1</i> founder mutation in the Roma population causes recessive variant of H-ABC. Neurology, 2017, 89, 1821-1828.	1.5	39
299	Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations. Orphanet Journal of Rare Diseases, 2017, 12, 89.	1.2	39
300	Defining the electroclinical phenotype and outcome of PCDH19â€related epilepsy: A multicenter study. Epilepsia, 2018, 59, 2260-2271.	2.6	39
301	Familial severe myoclonic epilepsy of infancy: truncation of Nav1.1 and genetic heterogeneity. Epileptic Disorders, 2003, 5, 21-5.	0.7	39
302	X-linked congenital ataxia: A clinical and genetic study. , 2000, 92, 53-56.		38
303	POMGnT1 Mutations in Congenital Muscular Dystrophy. Archives of Neurology, 2006, 63, 1491.	4.9	38
304	POMT1 and POMT2 mutations in CMD patients: A multicentric Italian study. Neuromuscular Disorders, 2008, 18, 565-571.	0.3	38
305	Expanding <i>CEP290</i> mutational spectrum in ciliopathies. American Journal of Medical Genetics, Part A, 2009, 149A, 2173-2180.	0.7	38
306	Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases. Neuromuscular Disorders, 2012, 22, S226-S229.	0.3	38

#	Article	IF	CITATIONS
307	C19orf12 and FA2H Mutations Are Rare in Italian Patients With Neurodegeneration With Brain Iron Accumulation. Seminars in Pediatric Neurology, 2012, 19, 75-81.	1.0	38
308	Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience. Neuromuscular Disorders, 2017, 27, 1084-1086.	0.3	38
309	Novel mutations in IBA57 are associated with leukodystrophy and variable clinical phenotypes. Journal of Neurology, 2017, 264, 102-111.	1.8	38
310	Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?. PLoS ONE, 2020, 15, e0230677.	1.1	38
311	Clinical spectrum of POLR3-related leukodystrophy caused by biallelic <i>POLR1C</i> pathogenic variants. Neurology: Genetics, 2019, 5, e369.	0.9	38
312	Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. Neurology, 1998, 51, 592-595.	1.5	37
313	A novel SURF1 mutation results in Leigh syndrome with peripheral neuropathy caused by cytochrome c oxidase deficiency. Neuromuscular Disorders, 2000, 10, 450-453.	0.3	37
314	Incomplete penetrance in an <i>SPG3A</i> -linked family with a new mutation in the <i>atlastin</i> gene. Neurology, 2004, 62, 2138-2139.	1.5	37
315	Cardiac and Pulmonary Investigations in Bethlem Myopathy. Archives of Neurology, 2006, 63, 1617.	4.9	37
316	Myosin as a potential redox-sensor: an inÂvitro study. Journal of Muscle Research and Cell Motility, 2008, 29, 119-126.	0.9	37
317	"Mitochondrial neuropathiesâ€ŧ A survey from the large cohort of the Italian Network. Neuromuscular Disorders, 2016, 26, 272-276.	0.3	37
318	Missense mutations of CACNA1A are a frequent cause of autosomal dominant nonprogressive congenital ataxia. European Journal of Paediatric Neurology, 2017, 21, 450-456.	0.7	37
319	A clinical diagnostic algorithm for early onset cerebellar ataxia. European Journal of Paediatric Neurology, 2019, 23, 692-706.	0.7	37
320	Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 638-639.	0.9	36
321	Congenital muscular dystrophy associated with calf hypertrophy, microcephaly and severe mental retardation in three Italian families: evidence for a novel CMD syndrome. Neuromuscular Disorders, 2000, 10, 541-547.	0.3	36
322	Brown–Vialetto–van Laere and Fazio–Londe overlap syndromes: A clinical, biochemical and genetic study. Neuromuscular Disorders, 2012, 22, 1075-1082.	0.3	36
323	Nrf2 Induction Re-establishes a Proper Neuronal Differentiation Program in Friedreich's Ataxia Neural Stem Cells. Frontiers in Cellular Neuroscience, 2019, 13, 356.	1.8	36
324	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2020, 7, 786-798.	1.7	36

#	Article	IF	CITATIONS
325	Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study. Neurology, 2021, 96, e587-e599.	1.5	36
326	Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias. International Journal of Molecular Sciences, 2020, 21, 3603.	1.8	36
327	High dose immunoglobulin IV treatment in adrenoleukodystrophy Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 69-71.	0.9	35
328	Genomic rearrangements at the IGHMBP2 gene locus in two patients with SMARD1. Human Genetics, 2004, 115, 319-326.	1.8	35
329	New clinical and molecular insights on Barth syndrome. Orphanet Journal of Rare Diseases, 2013, 8, 27.	1.2	35
330	Type I SMA "new natural historyâ€i longâ€term data in nusinersenâ€treated patients. Annals of Clinical and Translational Neurology, 2021, 8, 548-557.	1.7	35
331	Determination of superoxide dismutase and glutathione peroxidase activities in blood of healthy pediatric subjects. Clinica Chimica Acta, 2002, 322, 117-120.	0.5	34
332	Exome sequencing in a family with intellectual disability, early onset spasticity, and cerebellar atrophy detects a novel mutation in EXOSC3. Neurogenetics, 2013, 14, 247-250.	0.7	34
333	Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 14-18.	0.3	34
334	A novel LAMP2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review. Cardiovascular Pathology, 2016, 25, 423-431.	0.7	34
335	<scp>DJ</scp> â€1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of <scp>PARK7</scp> . Clinical Genetics, 2017, 92, 18-25.	1.0	34
336	Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp> . Annals of Neurology, 2020, 88, 1109-1117.	2.8	34
337	The spectrum of the so-called rigid spine syndrome: nosological considerations and report of three female cases. Journal of Neurology, 1986, 233, 248-253.	1.8	33
338	Epilepsia partialis continua and neuronal migration anomalies. Brain and Development, 1992, 14, 323-328.	0.6	33
339	Pathogenetic mechanisms in hereditary dysfunctions of complex I of the respiratory chain in neurological diseases. Biochimica Et Biophysica Acta - Bioenergetics, 2009, 1787, 502-517.	0.5	33
340	Myoclonus in mitochondrial disorders. Movement Disorders, 2014, 29, 722-728.	2.2	33
341	Spinal muscular atrophy associated with progressive myoclonic epilepsy: A rare condition caused by mutations in <i><scp>ASAH</scp>1</i> . Epilepsia, 2015, 56, 692-698.	2.6	33
342	The phenotypic and molecular spectrum of PEHO syndrome and PEHO-like disorders. Brain, 2017, 140, e49-e49.	3.7	33

#	Article	IF	CITATIONS
343	Cardiac and Neuromuscular Features of Patients With <i>LMNA</i> -Related Cardiomyopathy. Annals of Internal Medicine, 2019, 171, 458.	2.0	33
344	Diagnostic Yield of a Targeted Next-Generation Sequencing Gene Panel for Pediatric-Onset Movement Disorders: A 3-Year Cohort Study. Frontiers in Genetics, 2019, 10, 1026.	1.1	33
345	Phenotypic Heterogeneity in Two Unrelated Danon Patients Associated with the SameLAMPâ€2Gene Mutation. Neuropediatrics, 2005, 36, 309-313.	0.3	32
346	Molecular Genetic Analysis of the PLP1 Gene in 38 Families with PLP1-related disorders: Identification and Functional Characterization of 11 Novel PLP1 Mutations. Orphanet Journal of Rare Diseases, 2011, 6, 40.	1.2	32
347	Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS ONE, 2016, 11, e0151445.	1.1	32
348	Megalencephalic leukoencephalopathy with subcortical cysts protein-1 regulates epidermal growth factor receptor signaling in astrocytes. Human Molecular Genetics, 2016, 25, 1543-1558.	1.4	32
349	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.3	32
350	Revisiting mitochondrial ocular myopathies: a study from the Italian Network. Journal of Neurology, 2017, 264, 1777-1784.	1.8	32
351	Nonprogressive congenital ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 155, 91-103.	1.0	32
352	Myelinated retinal fibers in autosomal recessive spastic ataxia of Charlevoix-Saguenay. European Journal of Neurology, 2011, 18, 1187-1190.	1.7	31
353	Cardiomyopathy in patients with POMT1-related congenital and limb-girdle muscular dystrophy. European Journal of Human Genetics, 2012, 20, 1234-1239.	1.4	31
354	Zellweger Spectrum Disorder with Mild Phenotype Caused by PEX2 Gene Mutations. JIMD Reports, 2012, 6, 43-46.	0.7	31
355	Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. Neuromuscular Disorders, 2012, 22, 685-689.	0.3	31
356	Riboflavin transporter 3 involvement in infantile Brown-Vialetto-Van Laere disease: two novel mutations. Journal of Medical Genetics, 2013, 50, 104-107.	1.5	31
357	Persistent pulmonary arterial hypertension in the newborn (PPHN): A frequent manifestation of TMEM70 defective patients. Molecular Genetics and Metabolism, 2014, 111, 353-359.	0.5	31
358	Mutations in <i>ELAC2</i> associated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3′â€end processing. Human Mutation, 2019, 40, 1731-1748.	1.1	31
359	Clinical-genetic features and peculiar muscle histopathology in infantile <i>DNM1L</i> -related mitochondrial epileptic encephalopathy. Human Mutation, 2019, 40, 601-618.	1.1	31
360	Bilateral, Reversible, Selective Thalamic Involvement Demonstrated by Brain MR and Acute Severe Neurological Dysfunction with Favorable Outcome*. Neuropediatrics, 1994, 25, 44-47.	0.3	30

#	Article	IF	CITATIONS
361	Fatal infantile leukodystrophy: A severe variant of CACH/VWM syndrome, allelic to chromosome 3q27. Neurology, 2002, 58, 161-162.	1.5	30
362	Hypertrophic cardiomyopathy and mtDNA depletion. Successful treatment with heart transplantation. Neuromuscular Disorders, 2002, 12, 56-59.	0.3	30
363	Hypertrophic cardiomyopathy, cataract, developmental delay, lactic acidosis: A novel subtype of 3-methylglutaconic aciduria. Journal of Inherited Metabolic Disease, 2006, 29, 546-550.	1.7	30
364	Heart transplantation in a child with LGMD2I presenting as isolated dilated cardiomyopathy. Neuromuscular Disorders, 2008, 18, 153-155.	0.3	30
365	Fetal akinesia in metatropic dysplasia: The combined phenotype of chondrodysplasia and neuropathy?. American Journal of Medical Genetics, Part A, 2011, 155, 2860-2864.	0.7	30
366	Oral-facial-digital syndrome type VI: is C5orf42 really the major gene?. Human Genetics, 2015, 134, 123-126.	1.8	30
367	Mutations in the <scp>IRBIT</scp> domain of <i><scp>ITPR1</scp></i> are a frequent cause of autosomal dominant nonprogressive congenital ataxia. Clinical Genetics, 2017, 91, 86-91.	1.0	30
368	Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment. Genetics in Medicine, 2020, 22, 1851-1862.	1.1	30
369	Characterizing PCDH19 in human induced pluripotent stem cells (iPSCs) and iPSC-derived developing neurons: emerging role of a protein involved in controlling polarity during neurogenesis. Oncotarget, 2015, 6, 26804-26813.	0.8	30
370	Reducing body myopathy and desmin storage in skeletal muscle: morphological and biochemical findings. Acta Neuropathologica, 1994, 87, 106-112.	3.9	29
371	Atypical Leigh syndrome associated with the D393N mutation in the mitochondrial ND5 subunit. Neurology, 2003, 61, 1017-1018.	1.5	29
372	Cystic leukoencephalopathy without megalencephaly. Neurology, 2005, 64, 1411-1416.	1.5	29
373	A congenital myopathy with diaphragmatic weakness not linked to the SMARD1 locus. Neuromuscular Disorders, 2007, 17, 174-179.	0.3	29
374	166th ENMC International Workshop on Collagen type VI-related Myopathies, 22–24 May 2009, Naarden, The Netherlands. Neuromuscular Disorders, 2010, 20, 346-354.	0.3	29
375	Effect of protein glutathionylation on neuronal cytoskeleton: a potential link to neurodegeneration. Neuroscience, 2011, 192, 285-294.	1.1	29
376	Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations. Neurogenetics, 2016, 17, 65-70.	0.7	29
377	Defective kinesin binding of TUBB2A causes progressive spastic ataxia syndrome resembling sacsinopathy. Human Molecular Genetics, 2018, 27, 1892-1904.	1.4	29
378	Development of an academic disease registry for spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 794-799.	0.3	29

#	Article	IF	CITATIONS
379	Molecular Genetics and Interferon Signature in the Italian Aicardi Goutières Syndrome Cohort: Report of 12 New Cases and Literature Review. Journal of Clinical Medicine, 2019, 8, 750.	1.0	29
380	A homozygous MRPL24 mutation causes a complex movement disorder and affects the mitoribosome assembly. Neurobiology of Disease, 2020, 141, 104880.	2.1	29
381	Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen. Neuromuscular Disorders, 2021, 31, 596-602.	0.3	29
382	Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. Journal of Comparative Effectiveness Research, 2022, 11, 139-155.	0.6	29
383	Neurophysiologic follow-up of long-term dietary treatment in adult-onset adrenoleukodystrophy. Neurology, 1999, 52, 810-810.	1.5	28
384	Determination of glutathionyl-hemoglobin in human erythrocytes by cation-exchange high-performance liquid chromatography. Analytical Biochemistry, 2003, 312, 85-90.	1.1	28
385	CONGENITAL MUSCULAR DYSTROPHY WITH DEFECTIVE α-DYSTROGLYCAN, CEREBELLAR HYPOPLASIA, AND EPILEPSY. Neurology, 2009, 73, 1599-1601.	1.5	28
386	A Novel Mutation in <i>RPL10</i> (Ribosomal Protein L10) Causes X-Linked Intellectual Disability, Cerebellar Hypoplasia, and Spondylo-Epiphyseal Dysplasia. Human Mutation, 2015, 36, 1155-1158.	1.1	28
387	PCDH19-related epilepsy and Dravet Syndrome: Face-off between two early-onset epilepsies with fever sensitivity. Epilepsy Research, 2016, 125, 32-36.	0.8	28
388	Involvement of respiratory muscles in cytoplasmic body myopathy — A pathological study—. Brain and Development, 1990, 12, 798-806.	0.6	27
389	Seven novel mutations in the ORNT1 gene (SLC25A15) in patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Human Mutation, 2001, 18, 460-460.	1.1	27
390	Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. Journal of Neurology, 2002, 249, 200-205.	1.8	27
391	Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Molecular and Cellular Neurosciences, 2003, 23, 219-231.	1.0	27
392	Altered expression of the MCSP/NG2 chondroitin sulfate proteoglycan in collagen VI deficiency. Molecular and Cellular Neurosciences, 2005, 30, 408-417.	1.0	27
393	Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies. BMC Medical Genetics, 2010, 11, 44.	2.1	27
394	A new locus on 3p23–p25 for an autosomal-dominant limb-girdle muscular dystrophy, LGMD1H. European Journal of Human Genetics, 2010, 18, 636-641.	1.4	27
395	Congenital muscular dystrophies with cognitive impairment. Neurology, 2010, 75, 898-903.	1.5	27
396	X-linked disorders with cerebellar dysgenesis. Orphanet Journal of Rare Diseases, 2011, 6, 24.	1.2	27

#	Article	IF	CITATIONS
397	Somatic mosaicism of PCDH19 mutation in a family with low-penetrance EFMR. Neurogenetics, 2012, 13, 341-345.	0.7	27
398	Altered <i>PLP1</i> splicing causes hypomyelination of early myelinating structures. Annals of Clinical and Translational Neurology, 2015, 2, 648-661.	1.7	27
399	Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs. Journal of the Neurological Sciences, 2015, 356, 65-71.	0.3	27
400	Frataxin silencing alters microtubule stability in motor neurons: implications for Friedreich's ataxia. Human Molecular Genetics, 2016, 25, 4288-4301.	1.4	27
401	Novel mutations in <i><scp>KARS</scp></i> cause hypertrophic cardiomyopathy and combined mitochondrial respiratory chain defect. Clinical Genetics, 2017, 91, 918-923.	1.0	27
402	Insights from genotype–phenotype correlations by novel SPEG mutations causing centronuclear myopathy. Neuromuscular Disorders, 2017, 27, 836-842.	0.3	27
403	Identification of novel and hotspot mutations in the channel domain of ITPR1 in two patients with Gillespie syndrome. Gene, 2017, 628, 141-145.	1.0	27
404	Aged induced pluripotent stem cell (iPSCs) as a new cellular model for studying premature aging. Aging, 2017, 9, 1453-1469.	1.4	27
405	Heterozygous missense variants of <i>SPTBN2</i> are a frequent cause of congenital cerebellar ataxia. Clinical Genetics, 2019, 96, 169-175.	1.0	27
406	The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich's Ataxia. International Journal of Molecular Sciences, 2020, 21, 916.	1.8	27
407	Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2021, 8, 1622-1634.	1.7	27
408	Clinical and electrophysiological features of epilepsy in Italian patients with CLN8 mutations. Epilepsy and Behavior, 2007, 10, 187-191.	0.9	26
409	Congenital myopathies. Current Neurology and Neuroscience Reports, 2008, 8, 73-79.	2.0	26
410	Protein glutathionylation increases in the liver of patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e457-64.	1.4	26
411	Assaying ATP synthesis in cultured cells: A valuable tool for the diagnosis of patients with mitochondrial disorders. Biochemical and Biophysical Research Communications, 2009, 383, 58-62.	1.0	26
412	GSSG-mediated Complex I defect in isolated cardiac mitochondria. International Journal of Molecular Medicine, 2010, 26, 95-9.	1.8	26
413	Limb-girdle muscular dystrophy with α-dystroglycan deficiency and mutations in the <i>ISPD</i> gene. Neurology, 2013, 80, 963-965.	1.5	26
414	Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study. Orphanet Journal of Rare Diseases, 2018, 13, 170.	1.2	26

#	Article	IF	CITATIONS
415	Genome sequencing in persistently unsolved white matter disorders. Annals of Clinical and Translational Neurology, 2020, 7, 144-152.	1.7	26
416	Age and sex prevalence estimate of Joubert syndrome in Italy. Neurology, 2020, 94, e797-e801.	1.5	26
417	HyperCKemia as the Only Sign of McArdle's Disease in a Child. Journal of Child Neurology, 2000, 15, 137-138.	0.7	25
418	Vacuolating megalencephalic leukoencephalopathy with subcortical cysts: functional studies of novel variants inMLC1. Human Mutation, 2006, 27, 292-292.	1.1	25
419	Prenatal ultrasound and magnetic resonance imaging features in a fetus with Walker–Warburg syndrome. Ultrasound in Obstetrics and Gynecology, 2009, 33, 363-365.	0.9	25
420	TMEM70: a mutational hot spot in nuclear ATP synthase deficiency with a pivotal role in complex V biogenesis. Neurogenetics, 2012, 13, 375-386.	0.7	25
421	Novel findings associated with MTM1 suggest a higher number of female symptomatic carriers. Neuromuscular Disorders, 2016, 26, 292-299.	0.3	25
422	Microcephaly, intractable seizures and developmental delay caused by biallelic variants in <i><scp>TBCD</scp></i> : further delineation of a new chaperoneâ€mediated tubulinopathy. Clinical Genetics, 2017, 91, 725-738.	1.0	25
423	ISCA1 mutation in a patient with infantile-onset leukodystrophy causes defects in mitochondrial [4Fe–4S] proteins. Human Molecular Genetics, 2018, 27, 2739-2754.	1.4	25
424	Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review. Parkinsonism and Related Disorders, 2019, 68, 8-16.	1.1	25
425	Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscular Disorders, 2020, 30, 756-764.	0.3	25
426	Mitochondrial Dynamics: Molecular Mechanisms, Related Primary Mitochondrial Disorders and Therapeutic Approaches. Genes, 2021, 12, 247.	1.0	25
427	Manifesting heterozygotes in McArdle's disease: clinical, morphological and biochemical studies in a family. Journal of the Neurological Sciences, 1993, 115, 91-94.	0.3	24
428	Ullrich myopathy phenotype with secondary ColVI defect identified by confocal imaging and electron microscopy analysis. Neuromuscular Disorders, 2007, 17, 587-596.	0.3	24
429	TUBB4A-related hypomyelinating leukodystrophy: New insights from a series of 12 patients. European Journal of Paediatric Neurology, 2016, 20, 323-330.	0.7	24
430	A novel mutation in <i><scp>NDUFB11</scp></i> unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia. Clinical Genetics, 2017, 91, 441-447.	1.0	24
431	Childhood Rapid-Onset Ataxia: Expanding the Phenotypic Spectrum of ATP1A3 Mutations. Cerebellum, 2018, 17, 489-493.	1.4	24
432	Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphiâ€based international workshop. Journal of Inherited Metabolic Disease, 2018, 41, 1267-1273.	1.7	24

#	Article	IF	CITATIONS
433	An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology, 2018, 91, e696-e703.	1.5	24
434	Italian recommendations for diagnosis and management of congenital myasthenic syndromes. Neurological Sciences, 2019, 40, 457-468.	0.9	24
435	The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys. PLOS Currents, 2014, 6, .	1.4	24
436	All glutathione forms are depleted in blood of obese and type 1 diabetic children. Pediatric Diabetes, 2012, 13, 272-277.	1.2	23
437	Metabolic neuropathies and myopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1437-1455.	1.0	23
438	Conventional magnetic resonance imaging and diffusion tensor imaging studies in children with novel GPR56 mutations: further delineation of a cobblestone-like phenotype. Neurogenetics, 2013, 14, 77-83.	0.7	23
439	Description of a novel TUBA1A mutation in Arg-390 associated with asymmetrical polymicrogyria and mid-hindbrain dysgenesis. European Journal of Paediatric Neurology, 2013, 17, 361-365.	0.7	23
440	ATP1A3 -related epileptic encephalopathy responding to ketogenic diet. Brain and Development, 2018, 40, 433-438.	0.6	23
441	Longitudinal natural history in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2019, 29, 857-862.	0.3	23
442	Clinical and radiological profile of patients with spinal muscular atrophy type 4. European Journal of Neurology, 2021, 28, 609-619.	1.7	23
443	Aged iPSCs display an uncommon mitochondrial appearance and fail to undergo in vitro neurogenesis. Aging, 2014, 6, 1094-1108.	1.4	23
444	Spinal muscular atrophies: recent insights and impact on molecular diagnosis. Journal of Molecular Medicine, 1996, 74, 555-562.	1.7	22
445	Lyonization Effects of the t(X;16) Translocation on the Phenotypic Expression in a Rare Female With Menkes Disease. Pediatric Research, 2009, 65, 347-351.	1.1	22
446	FGF17, a gene involved in cerebellar development, is downregulated in a patient with Dandy–Walker malformation carrying a de novo 8p deletion. Neurogenetics, 2011, 12, 241-245.	0.7	22
447	PRRT2 is mutated in familial and non-familial benign infantile seizures. European Journal of Paediatric Neurology, 2013, 17, 77-81.	0.7	22
448	Frataxin Silencing Inactivates Mitochondrial Complex I in NSC34 Motoneuronal Cells and Alters Glutathione Homeostasis. International Journal of Molecular Sciences, 2014, 15, 5789-5806.	1.8	22
449	Christianson Syndrome: Spectrum of Neuroimaging Findings. Neuropediatrics, 2014, 45, 247-251.	0.3	22
450	Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations. Neurogenetics, 2014, 15, 41-48.	0.7	22

#	Article	IF	CITATIONS
451	Cognitive, adaptive, and behavioral features in Joubert syndrome. American Journal of Medical Genetics, Part A, 2016, 170, 3115-3124.	0.7	22
452	Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown–Vialetto disease that is partially rescued by riboflavin. Scientific Reports, 2017, 7, 46271.	1.6	22
453	Clinical, biochemical, and genetic features associated with <i>VARS2</i> -related mitochondrial disease. Human Mutation, 2018, 39, 563-578.	1.1	22
454	A novel KCTD17 mutation is associated with childhood early-onset hyperkinetic movement disorder. Parkinsonism and Related Disorders, 2019, 61, 4-6.	1.1	22
455	Nusinersen efficacy data for 24â€month in type 2 and 3 spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 404-409.	1.7	22
456	Bilateral striatal necrosis, dystonia and optic atrophy in two siblings Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 16-19.	0.9	21
457	PLP1 and GPM6B intragenic copy number analysis by MAPH in 262 patients with hypomyelinating leukodystrophies: identification of one partial triplication and two partial deletions of PLP1. Neurogenetics, 2006, 7, 31-37.	0.7	21
458	Megalencephalic leukoencephalopathy with subcortical cysts type 1 (MLC1) due to a homozygous deep intronic splicing mutation (c.895-226T>C) abrogated in vitro using an antisense morpholino oligonucleotide. Neurogenetics, 2012, 13, 205-214.	0.7	21
459	Functional and Gait Assessment in Children and Adolescents Affected by Friedreich's Ataxia: A One-Year Longitudinal Study. PLoS ONE, 2016, 11, e0162463.	1.1	21
460	Expanding the clinical phenotype of CAPN1- associated mutations: A new case with congenital-onset pure spastic paraplegia. Journal of the Neurological Sciences, 2017, 378, 210-212.	0.3	21
461	Development of SaraHome: A novel, well-accepted, technology-based assessment tool for patients with ataxia. Computer Methods and Programs in Biomedicine, 2020, 188, 105257.	2.6	21
462	Ferroptosis in Friedreich's Ataxia: A Metal-Induced Neurodegenerative Disease. Biomolecules, 2020, 10, 1551.	1.8	21
463	Heterozygous <i>KIF1A</i> variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. Journal of Medical Genetics, 2021, 58, 475-483.	1.5	21
464	Multi-minicore disease–searching for boundaries: phenotype analysis of 38 cases. Annals of Neurology, 2000, 48, 745-57.	2.8	21
465	Giant axonal neuropathy: report on a case with focal fiber loss. Acta Neuropathologica, 1992, 83, 543-546.	3.9	20
466	Defective dendritic cell maturation in a child with nucleotide excision repair deficiency and CD4 lymphopenia. Clinical and Experimental Immunology, 2001, 126, 511-518.	1.1	20
467	Major myofibrillar changes in early onset myopathy due to de novo heterozygous missense mutation in lamin A/C gene. Neuromuscular Disorders, 2005, 15, 847-850.	0.3	20
468	Susceptibility of isolated myofibrils to in vitro glutathionylation: Potential relevance to muscle functions. Cytoskeleton, 2010, 67, 81-89.	1.0	20

#	Article	IF	CITATIONS
469	Insertion of 16 amino acids in the BAR domain of the oligophrenin 1 protein causes mental retardation and cerebellar hypoplasia in an Italian family. Human Mutation, 2011, 32, E2294-E2307.	1.1	20
470	Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. European Journal of Paediatric Neurology, 2012, 16, 301-303.	0.7	20
471	Megalencephalic leukoencephalopathy with subcortical cysts protein-1 modulates endosomal pH and protein trafficking in astrocytes: Relevance to MLC disease pathogenesis. Neurobiology of Disease, 2014, 66, 1-18.	2.1	20
472	TUBB Variants Underlying Different Phenotypes Result in Altered Vesicle Trafficking and Microtubule Dynamics. International Journal of Molecular Sciences, 2020, 21, 1385.	1.8	20
473	A Novel Insertion Mutation (A169i) in the CLN1 Gene Is Associated with Infantile Neuronal Ceroid Lipofuscinosis in an Italian Patient. Biochemical and Biophysical Research Communications, 1998, 245, 519-522.	1.0	19
474	Visual quality metrics. , 2006, , .		19
475	Genotype–phenotype correlation in five Pelizaeus–Merzbacher disease patients with <i>PLP1 </i> gene duplications. Clinical Genetics, 2008, 73, 279-287.	1.0	19
476	Transcriptional behavior of DMD gene duplications in DMD/BMD males. Human Mutation, 2009, 30, E310-E319.	1.1	19
477	Infantile Childhood Onset of Spinocerebellar Ataxia Type 2. Cerebellum, 2012, 11, 526-530.	1.4	19
478	Dandy-Walker malformation and Wisconsin syndrome: novel cases add further insight into the genotype-phenotype correlations of 3q23q25 deletions. Orphanet Journal of Rare Diseases, 2013, 8, 75.	1.2	19
479	PRRT2 mutation causes paroxysmal kinesigenic dyskinesia and hemiplegic migraine in monozygotic twins. European Journal of Paediatric Neurology, 2013, 17, 254-258.	0.7	19
480	Monocytes and macrophages as biomarkers for the diagnosis of megalencephalic leukoencephalopathy with subcortical cysts. Molecular and Cellular Neurosciences, 2013, 56, 307-321.	1.0	19
481	Mutation of <i><scp>CHRNA</scp>2</i> in a family with benign familial infantile seizures: Potential role of nicotinic acetylcholine receptor in various phenotypes of epilepsy. Epilepsia, 2015, 56, e53-7.	2.6	19
482	Defining the clinical-genetic and neuroradiological features in SPG54: description of eight additional cases and nine novel DDHD2 variants. Journal of Neurology, 2019, 266, 2657-2664.	1.8	19
483	APOPT 1/ COA 8 assists COX assembly and is oppositely regulated by UPS and ROS. EMBO Molecular Medicine, 2019, 11, .	3.3	19
484	Natural history of a cohort of <i><scp>ABCD</scp>1</i> variant female carriers. European Journal of Neurology, 2019, 26, 326-332.	1.7	19
485	Growth patterns in children with spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 375.	1.2	19
486	Quality Metrics for 2D Scatterplot Graphics: Automatically Reducing Visual Clutter. Lecture Notes in Computer Science, 2004, , 77-89.	1.0	19

#	Article	IF	CITATIONS
487	<i>SUFU</i> haploinsufficiency causes a recognisable neurodevelopmental phenotype at the mild end of the Joubert syndrome spectrum. Journal of Medical Genetics, 2022, 59, 888-894.	1.5	19
488	Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders, 2012, 22, 546-548.	0.3	18
489	Childhood-onset ATP1A3-related conditions: Report of two new cases of phenotypic spectrum. Parkinsonism and Related Disorders, 2016, 30, 81-82.	1.1	18
490	Biallelic mutations in the homeodomain of NKX6-2 underlie a severe hypomyelinating leukodystrophy. Brain, 2017, 140, 2550-2556.	3.7	18
491	Clinical, radiological, and genetic characteristics of 16 patients with <i>ACO2</i> gene defects: Delineation of an emerging neurometabolic syndrome. Journal of Inherited Metabolic Disease, 2019, 42, 264-275.	1.7	18
492	<i>RARS1</i> â€related hypomyelinating leukodystrophy: Expanding the spectrum. Annals of Clinical and Translational Neurology, 2020, 7, 83-93.	1.7	18
493	Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle and Nerve, 2021, 64, 552-559.	1.0	18
494	Autosomal recessive hypermyelinating neuropathy. Acta Neuropathologica, 1994, 87, 337-342.	3.9	17
495	HiTSEE KNIME: a visualization tool for hit selection and analysis in high-throughput screening experiments for the KNIME platform. BMC Bioinformatics, 2012, 13, S4.	1.2	17
496	A new de novo missense mutation in MYH2 expands clinical and genetic findings in hereditary myosin myopathies. Neuromuscular Disorders, 2013, 23, 437-440.	0.3	17
497	Efficacy of Miglustat in Niemann–Pick C disease: A single centre experience. Molecular Genetics and Metabolism, 2013, 110, 329-335.	0.5	17
498	Diffusion tensor imaging in <i>SPG11</i> - and <i>SPG4</i> -linked hereditary spastic paraplegia. International Journal of Neuroscience, 2014, 124, 261-270.	0.8	17
499	Orthopedic Management of Scoliosis by Garches Brace and Spinal Fusion in SMA Type 2 Children. Journal of Neuromuscular Diseases, 2015, 2, 453-462.	1.1	17
500	New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients. Journal of Molecular Neuroscience, 2016, 59, 351-359.	1.1	17
501	Start codon mutation of GYG1 causing late-onset polyglucosan body myopathy with nemaline rods. Journal of Neurology, 2016, 263, 2133-2135.	1.8	17
502	Rho Kinase Inhibition Is Essential During In Vitro Neurogenesis and Promotes Phenotypic Rescue of Human Induced Pluripotent Stem Cell-Derived Neurons With Oligophrenin-1 Loss of Function. Stem Cells Translational Medicine, 2016, 5, 860-869.	1.6	17
503	Dolichol-phosphate mannose synthase depletion in zebrafish leads to dystrophic muscle with hypoglycosylated α-dystroglycan. Biochemical and Biophysical Research Communications, 2016, 477, 137-143.	1.0	17
504	De novo p.T362R mutation in MORC2 causes early onset cerebellar ataxia, axonal polyneuropathy and nocturnal hypoventilation. Brain, 2017, 140, e34-e34.	3.7	17

#	Article	IF	CITATIONS
505	A novel PMCA3 mutation in an ataxic patient with hypomorphic phosphomannomutase 2 (PMM2) heterozygote mutations: Biochemical characterization of the pump defect. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 3303-3312.	1.8	17
506	X-linked ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 155, 175-189.	1.0	17
507	Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy. International Journal of Cardiology, 2019, 280, 99-103.	0.8	17
508	Validation of low-cost system for gait assessment in children with ataxia. Computer Methods and Programs in Biomedicine, 2020, 196, 105705.	2.6	17
509	Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement. Biomolecules, 2020, 10, 702.	1.8	17
510	Movement disorders in MCT8 deficiency/Allan-Herndon-Dudley Syndrome. Molecular Genetics and Metabolism, 2022, 135, 109-113.	0.5	17
511	Congenital X-linked ataxia, progressive myoclonic encephalopathy, macular degeneration and recurrent infections. American Journal of Medical Genetics Part A, 1992, 43, 443-451.	2.4	16
512	Golli-MBP Copy Number Analysis by FISH, QMPSF and MAPH in 195 Patients with Hypomyelinating Leukodystrophies. Annals of Human Genetics, 2006, 70, 66-77.	0.3	16
513	Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies. Neuromuscular Disorders, 2011, 21, 194-203.	0.3	16
514	Activating <i>PIK3CA</i> somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity. American Journal of Medical Genetics, Part A, 2014, 164, 2365-2369.	0.7	16
515	Deep RNA profiling identified clock and molecular clock genes as pathophysiological signatures in collagen VI myopathy. Journal of Cell Science, 2016, 129, 1671-84.	1.2	16
516	Clinical, imaging, biochemical and molecular features in Leigh syndrome: a study from the Italian network of mitochondrial diseases. Orphanet Journal of Rare Diseases, 2021, 16, 413.	1.2	16
517	Respiratory chain defects in hereditary spastic paraplegias. Neuromuscular Disorders, 2001, 11, 565-569.	0.3	15
518	Severe Abnormalities of the Pons in Two Infants with Goldenhar Syndrome. Neuropediatrics, 2004, 35, 234-238.	0.3	15
519	Simultaneous determination of ubiquinol and ubiquinone in skeletal muscle of pediatric patients. Analytical Biochemistry, 2005, 342, 352-355.	1.1	15
520	Novel and recurrent ALDH3A2 mutations in Italian patients with Sjögren–Larsson syndrome. Journal of Human Genetics, 2007, 52, 865-870.	1.1	15
521	Relevance of GJC2 promoter mutation in Pelizaeus-Merzbacher-like disease. Annals of Neurology, 2012, 71, 146-148.	2.8	15
522	Somatic mosaicism in TPM2-related myopathy with nemaline rods and cap structures. Acta Neuropathologica, 2013, 125, 169-171.	3.9	15

#	Article	IF	CITATIONS
523	Muscle magnetic resonance imaging and histopathology in <i>ACTA1â€</i> related congenital nemaline myopathy. Muscle and Nerve, 2014, 50, 1011-1016.	1.0	15
524	Familial periventricular nodular heterotopia, epilepsy and Melnick–Needles Syndrome caused by a singleFLNAmutation with combined gain-of-function and loss-of-function effects. Journal of Medical Genetics, 2015, 52, 405-412.	1.5	15
525	Muscle MRI in neutral lipid storage disease (NLSD). Journal of Neurology, 2017, 264, 1334-1342.	1.8	15
526	A V1143F mutation in the neuronal-enriched isoform 2 of the PMCA pump is linked with ataxia. Neurobiology of Disease, 2018, 115, 157-166.	2.1	15
527	Compound heterozygous missense and deep intronic variants in NDUFAF6 unraveled by exome sequencing and mRNA analysis. Journal of Human Genetics, 2018, 63, 563-568.	1.1	15
528	One-year outcome of coenzyme Q10 supplementation in ADCK3 ataxia (ARCA2). Cerebellum and Ataxias, 2019, 6, 15.	1.9	15
529	Impaired urinary concentration ability is a sensitive predictor of renal disease progression in Joubert syndrome. Nephrology Dialysis Transplantation, 2020, 35, 1195-1202.	0.4	15
530	Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscular Disorders, 2020, 30, 959-969.	0.3	15
531	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Frontiers in Neurology, 2021, 12, 677551.	1.1	15
532	Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1136-e1147.	1.8	15
533	Alpha-actin gene mutations and polymorphisms in Italian patients with nemaline myopathy. International Journal of Molecular Medicine, 2004, 13, 805-9.	1.8	15
534	New familial mitochondrial encephalopathy with macrocephaly, cardiomyopathy, and complex I deficiency. Annals of Neurology, 1997, 42, 661-665.	2.8	14
535	169th ENMC International Workshop Rare Structural Congenital Myopathies 6–8 November 2009, Naarden, The Netherlands. Neuromuscular Disorders, 2011, 21, 363-374.	0.3	14
536	Developmental Splicing Deregulation in Leukodystrophies Related to EIF2B Mutations. PLoS ONE, 2012, 7, e38264.	1.1	14
537	A new phenotypic variant in cleidocranial dysplasia (CCD) associated with mutation c.391C>T of the RUNX2 gene. BMJ Case Reports, 2012, 2012, bcr1220115422-bcr1220115422.	0.2	14
538	Oligophrenin-1 (OPHN1), a Gene Involved in X-Linked Intellectual Disability, Undergoes RNA Editing and Alternative Splicing during Human Brain Development. PLoS ONE, 2014, 9, e91351.	1.1	14
539	Clinical and imaging hallmarks of the <i>MYH7</i> â€related myopathy with severe axial involvement. Muscle and Nerve, 2018, 58, 224-234.	1.0	14
540	Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment. Neuromuscular Disorders, 2019, 29, 920-929.	0.3	14

#	Article	IF	CITATIONS
541	Hereditary spastic paraplegia is a novel phenotype for germline de novo <i>ATP1A1</i> mutation. Clinical Genetics, 2020, 97, 521-526.	1.0	14
542	Mitochondrial epilepsy: a cross-sectional nationwide Italian survey. Neurogenetics, 2020, 21, 87-96.	0.7	14
543	Novel 7-DHCR mutation in a child with Smith-Lemli-Opitz syndrome. , 2000, 91, 138-140.		13
544	Respiratory Complex I in Brain Development and Genetic Disease. Neurochemical Research, 2004, 29, 547-560.	1.6	13
545	Hereditary spastic paraplegias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1899-1912.	1.0	13
546	Muscle imaging in patients with tubular aggregate myopathy caused by mutations in STIM1. Neuromuscular Disorders, 2015, 25, 898-903.	0.3	13
547	â€~Amish Nemaline Myopathy' in 2 Italian siblings harbouring a novel homozygous mutation in Troponin-I gene. Neuromuscular Disorders, 2019, 29, 766-770.	0.3	13
548	Mitochondrial and Peroxisomal Alterations Contribute to Energy Dysmetabolism in Riboflavin Transporter Deficiency. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-19.	1.9	13
549	Clinical phenotypes of infantile onset CACNA1A-related disorder. European Journal of Paediatric Neurology, 2021, 30, 144-154.	0.7	13
550	Refining the mutational spectrum and gene–phenotype correlates in pontocerebellar hypoplasia: results of a multicentric study. Journal of Medical Genetics, 2022, 59, 399-409.	1.5	13
551	Dissecting the Role of PCDH19 in Clustering Epilepsy by Exploiting Patient-Specific Models of Neurogenesis. Journal of Clinical Medicine, 2021, 10, 2754.	1.0	13
552	SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples. ELife, 2021, 10, .	2.8	13
553	Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neuromuscular Disorders, 2022, 32, 36-42.	0.3	13
554	Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases. International Journal of Molecular Sciences, 2021, 22, 13674.	1.8	13
555	Xâ€linked congenital ataxia: A new locus maps to Xq25â€q27.1. American Journal of Medical Genetics, Part A, 2008, 146A, 593-600.	0.7	12
556	Novel mutation in mitochondrial Elongation Factor EF-Tu associated to dysplastic leukoencephalopathy and defective mitochondrial DNA translation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 961-967.	1.8	12
557	Core-rod myopathy due to a novel mutation in BTB/POZ domain of KBTBD13 manifesting as late onset LGMD. Acta Neuropathologica Communications, 2018, 6, 94.	2.4	12
558	Corticospinal tract damage in HHH syndrome: a metabolic cause of hereditary spastic paraplegia. Orphanet Journal of Rare Diseases, 2019, 14, 208.	1.2	12

#	Article	IF	CITATIONS
559	Speech and Language Disorders in Friedreich Ataxia: Highlights on Phenomenology, Assessment, and Therapy. Cerebellum, 2020, 19, 126-130.	1.4	12
560	Co-occurrence of mutations in KIF7 and KIAA0556 in Joubert syndrome with ocular coloboma, pituitary malformation and growth hormone deficiency: a case report and literature review. BMC Pediatrics, 2020, 20, 120.	0.7	12
561	Novel <i>NDUFA12</i> variants are associated with isolated complex I defect and variable clinical manifestation. Human Mutation, 2021, 42, 699-710.	1.1	12
562	Therapy Trial Design in Vanishing White Matter. Neurology: Genetics, 2022, 8, e657.	0.9	12
563	Ataxia, deafness, leukodystrophy: Inherited disorder of the white matter in three related patients. Neurology, 2000, 54, 2325-2328.	1.5	11
564	Expanding the histopathological spectrum of <i>CFL2</i> â€related myopathies. Clinical Genetics, 2018, 93, 1234-1239.	1.0	11
565	SLC2A1 mutations are a rare cause of pediatric-onset hereditary spastic paraplegia. European Journal of Paediatric Neurology, 2019, 23, 329-332.	0.7	11
566	Mitochondrial Abnormalities in Induced Pluripotent Stem Cells-Derived Motor Neurons from Patients with Riboflavin Transporter Deficiency. Antioxidants, 2020, 9, 1252.	2.2	11
567	Biallelic mutations in <i>RNF220</i> cause laminopathies featuring leukodystrophy, ataxia and deafness. Brain, 2021, 144, 3020-3035.	3.7	11
568	Senescence-associated ultrastructural features of long-term cultures of induced pluripotent stem cells (iPSCs). Aging, 2017, 9, 2209-2222.	1.4	11
569	Identifying the dynamics of actin and tubulin polymerization in iPSCs and in iPSC-derived neurons. Oncotarget, 2017, 8, 111096-111109.	0.8	11
570	Oxidative abnormalities in Menkes disease. Journal of Inherited Metabolic Disease, 2000, 23, 349-351.	1.7	10
571	Immune-mediated rippling muscle disease and myasthenia gravis. Journal of Neuroimmunology, 2016, 299, 59-61.	1.1	10
572	Novel Homozygous KCNJ10 Mutation in a Patient with Non-syndromic Early-Onset Cerebellar Ataxia. Cerebellum, 2018, 17, 499-503.	1.4	10
573	Non-invasive Focal Mechanical Vibrations Delivered by Wearable Devices: An Open-Label Pilot Study in Childhood Ataxia. Frontiers in Neurology, 2018, 9, 849.	1.1	10
574	Biallelic Variants in the Nuclear Pore Complex Protein NUP93 Are Associated with Non-progressive Congenital Ataxia. Cerebellum, 2019, 18, 422-432.	1.4	10
575	Spatio-temporal parameters of ataxia gait dataset obtained with the Kinect. Data in Brief, 2020, 32, 106307.	0.5	10
576	N-Acetylaspartylglutamate (NAAG) in Pelizaeusmerzbacher Disease. , 2006, 576, 353-359.		10

#	Article	IF	CITATIONS
577	X-linked congenital ataxia: a clinical and genetic study. American Journal of Medical Genetics Part A, 2000, 92, 53-6.	2.4	10
578	Presymptomatic diagnosis of spinal muscular atrophy (SMA) III confirmed by deletion analysis of the survival motor neuron gene. American Journal of Medical Genetics Part A, 1995, 59, 101-102.	2.4	9
579	A novel nonsense mutation (Q509X) in three Italian late-infantile neuronal ceroid-lipofuscinosis children. Human Mutation, 2000, 15, 577-577.	1.1	9
580	Characterization of a rare case of Ullrich congenital muscular dystrophy due to truncating mutations within the COL6A1 gene C-Terminal domain: a case report. BMC Medical Genetics, 2013, 14, 59.	2.1	9
581	Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care?. Neuropediatrics, 2015, 46, 033-036.	0.3	9
582	Cytoskeletal dynamics during in vitro neurogenesis of induced pluripotent stem cells (iPSCs). Molecular and Cellular Neurosciences, 2016, 77, 113-124.	1.0	9
583	Acute myeloid leukemia in a 3 years old child with cleidocranial dysplasia. Leukemia and Lymphoma, 2016, 57, 2189-2191.	0.6	9
584	A mild form of adenylosuccinate lyase deficiency in absence of typical brain MRI features diagnosed by whole exome sequencing. Italian Journal of Pediatrics, 2017, 43, 65.	1.0	9
585	The Potential of iPSCs for the Treatment of Premature Aging Disorders. International Journal of Molecular Sciences, 2017, 18, 2350.	1.8	9
586	Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. Clinical Neurology and Neurosurgery, 2018, 168, 60-63.	0.6	9
587	Cardiovascular Involvement in Pediatric Laminopathies. Report of Six Patients and Literature Revision. Frontiers in Pediatrics, 2020, 8, 374.	0.9	9
588	Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Frontiers in Genetics, 2020, 11, 605.	1.1	9
589	Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen. European Journal of Neurology, 2021, 28, 602-608.	1.7	9
590	Visual analysis of news streams with article threads. , 2010, , .		9
591	Clinical variability at the mild end of <i>BRAT1</i> â€related spectrum: Evidence from two families with genotype–phenotype discordance. Human Mutation, 2022, 43, 67-73.	1.1	9
592	Clinical-Genetic Features Influencing Disability in Spastic Paraplegia Type 4. Neurology: Genetics, 2022, 8, e664.	0.9	9
593	Clinical and Genetic Aspects of Phelan–McDermid Syndrome: An Interdisciplinary Approach to Management. Genes, 2022, 13, 504.	1.0	9
594	Biopsy diagnosis of a case of adult onset orthochromatic leukodystrophy. Clinical and brain biopsy findings. Italian Journal of Neurological Sciences, 1992, 13, 787-792.	0.1	8

#	Article	IF	CITATIONS
595	Myopathy and hypertrophic cardiomyopathy with selective lysis of thick filaments. Virchows Archiv A, Pathological Anatomy and Histopathology, 1993, 422, 327-331.	1.4	8
596	Remission in dihydroxyphenylalanine-responsive dystonia. Movement Disorders, 1995, 10, 223-223.	2.2	8
597	A Novel Mutation (R271X) in the Myotubularin Gene Causes a Severe Miotubular Myopathy. Human Heredity, 1999, 49, 59-60.	0.4	8
598	hGFRα-4: a new member of the GDNF receptor family and a candidate for NBIA. Pediatric Neurology, 2001, 25, 156-161.	1.0	8
599	Prenatal diagnosis of spinal muscular atrophy with respiratory distress (SMARD1) in a twin pregnancy. Prenatal Diagnosis, 2004, 24, 839-841.	1.1	8
600	A mitochondrial ATPase 6 mutation is associated with Leigh syndrome in a family and affects proton flow and adenosine triphosphate output when modeled in <i>Escherichia coli</i> . Acta Paediatrica, International Journal of Paediatrics, 2004, 93, 65-67.	0.7	8
601	Current methodological issues in the study of children with inherited neuromuscular disorders. Developmental Medicine and Child Neurology, 2008, 50, 417-421.	1.1	8
602	A new form of alphaâ€dystroglycanopathy associated with severe drugâ€resistant epilepsy and unusual EEG features. Epileptic Disorders, 2011, 13, 259-262.	0.7	8
603	Protein glutathionylation in cellular compartments: A constitutive redox signal. Redox Report, 2012, 17, 63-71.	1.4	8
604	Congenital-onset spastic paraplegia in a patient with TUBB4A mutation and mild hypomyelination. Journal of the Neurological Sciences, 2016, 368, 145-146.	0.3	8
605	<i><scp>PPP1R21</scp>â€</i> related syndromic intellectual disability: Report of an adult patient and review. American Journal of Medical Genetics, Part A, 2020, 182, 3014-3022.	0.7	8
606	A Recurrent Pathogenic Variant of INPP5K Underlies Autosomal Recessive Congenital Muscular Dystrophy With Cataracts and Intellectual Disability: Evidence for a Founder Effect in Southern Italy. Frontiers in Genetics, 2020, 11, 565868.	1.1	8
607	Antioxidant Amelioration of Riboflavin Transporter Deficiency in Motoneurons Derived from Patient-Specific Induced Pluripotent Stem Cells. International Journal of Molecular Sciences, 2020, 21, 7402.	1.8	8
608	Predictive energy equations for spinal muscular atrophy type I children. American Journal of Clinical Nutrition, 2020, 111, 983-996.	2.2	8
609	Friedreich ataxia in COVID-19 time: current impact and future possibilities. Cerebellum and Ataxias, 2021, 8, 4.	1.9	8
610	Movement Disorders in Children with a Mitochondrial Disease: A Cross-Sectional Survey from the Nationwide Italian Collaborative Network of Mitochondrial Diseases. Journal of Clinical Medicine, 2021, 10, 2063.	1.0	8
611	Expanded phenotype of AARS1-related white matter disease. Genetics in Medicine, 2021, 23, 2352-2359.	1.1	8
612	Presymptomatic diagnosis of SMA III by genotype analysis. American Journal of Medical Genetics Part A, 1993, 45, 408-411.	2.4	7

#	Article	IF	CITATIONS
613	Respiratory-chain and pyruvate metabolism defects: Italian collaborative survey on 72 patients. Journal of Inherited Metabolic Disease, 1996, 19, 143-148.	1.7	7
614	X-linked neurodegenerative syndrome with congenital ataxia, late-onset progressive myoclonic encephalopathy and selective macular degeneration, linked to Xp22.33-pter. , 1996, 64, 69-72.		7
615	X-linked adrenoleukodystrophy: first report of the Italian Study Group. Italian Journal of Neurological Sciences, 1998, 19, 315-319.	0.1	7
616	Detection of mutations in the ALD gene (ABCD1) in seven Italian families: Description of four novel mutations. Human Mutation, 2000, 16, 271-271.	1.1	7
617	Neonatal-onset nemaline myopathy mimicking congenital diaphragmatic hernia. Journal of Pediatric Surgery, 2007, 42, e19-e22.	0.8	7
618	Novel large-range mitochondrial DNA deletions and fatal multisystemic disorder with prominent hepatopathy. Biochemical and Biophysical Research Communications, 2011, 415, 300-304.	1.0	7
619	The empowerment of translational research: lessons from laminopathies. Orphanet Journal of Rare Diseases, 2012, 7, 37.	1.2	7
620	?????. Cerebrovascular Diseases, 2012, 33, 1a-1a.	0.8	7
621	High concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes. Experimental and Molecular Pathology, 2016, 100, 199-206.	0.9	7
622	Serum uric acid in Friedreich Ataxia. Clinical Biochemistry, 2018, 54, 139-141.	0.8	7
623	Deep intronic variation in splicing regulatory element of the ERCC8 gene associated with severe but long-term survival Cockayne syndrome. European Journal of Human Genetics, 2018, 26, 527-536.	1.4	7
624	Copy Number Variants Account for a Tiny Fraction of Undiagnosed Myopathic Patients. Genes, 2018, 9, 524.	1.0	7
625	The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure. Neuromuscular Disorders, 2021, 31, 409-418.	0.3	7
626	CASK related disorder: Epilepsy and developmental outcome. European Journal of Paediatric Neurology, 2021, 31, 61-69.	0.7	7
627	Biâ€allelic <i>KARS1</i> pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease. Human Mutation, 2021, 42, 745-761.	1.1	7
628	Upper Body Physical Rehabilitation for Children with Ataxia through IMU-Based Exergame. Journal of Clinical Medicine, 2022, 11, 1065.	1.0	7
629	Two novel missense mutations causing adrenoleukodystrophy in Italian patients. Molecular and Cellular Probes, 1999, 13, 179-182.	0.9	6
630	Stem cells in severe infantile spinal muscular atrophy. Neuromuscular Disorders, 2012, 22, 1105.	0.3	6

#	Article	IF	CITATIONS
631	Old measures and new scores in spinal muscular atrophy patients. Muscle and Nerve, 2015, 52, 435-437.	1.0	6
632	Novel Dominant Mutation in BIN1 Gene Causing Mild Centronuclear Myopathy Revealed by Myalgias and CK Elevation. Journal of Neuromuscular Diseases, 2016, 3, 111-114.	1.1	6
633	A new multiplex method for the diagnosis of peroxisomal disorders allowing simultaneous determination of plasma very-long-chain fatty acids, phytanic, pristanic, docosahexaenoic and bile acids by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Clinica Chimica Acta. 2016. 458. 159-164.	0.5	6
634	Longitudinal gait assessment in a stiff person syndrome. International Journal of Rehabilitation Research, 2018, 41, 377-379.	0.7	6
635	ISCA1 mutation in a patient with infantile-onset leukodystrophy causes defects in mitochondrial [4Fe–4S] proteins. Human Molecular Genetics, 2018, 27, 3650-3650.	1.4	6
636	Observations from a nationwide vigilance program in medical care for spinal muscular atrophy patients in Chile. Arquivos De Neuro-Psiquiatria, 2019, 77, 470-477.	0.3	6
637	SMA – THERAPY. Neuromuscular Disorders, 2020, 30, S123-S124.	0.3	6
638	Movement disorders in ADAR1 disease: Insights from a comprehensive cohort. Parkinsonism and Related Disorders, 2020, 79, 100-104.	1.1	6
639	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. PLoS ONE, 2021, 16, e0253882.	1.1	6
640	Pierre Robin syndrome and Wilms tumor: An unusual association. Medical and Pediatric Oncology, 2000, 35, 83-84.	1.0	5
641	N.P.4 03 The CHOP INTEND: A reliable motor scale for infants with neuromuscular disease. Neuromuscular Disorders, 2006, 16, 668.	0.3	5
642	Fibroblast autofluorescence in connective tissue disorders: a future tool for clinical and differential diagnosis?. Journal of Biomedical Optics, 2008, 13, 054025.	1.4	5
643	Mitochondrial Encephalomyopathies and Related Syndromes: Brief Review. Endocrine Development, 2009, , 38-52.	1.3	5
644	Cardiolipin content in mitochondria from cultured skin fibroblasts harboring mutations in the mitochondrial ATP6 gene. Journal of Bioenergetics and Biomembranes, 2011, 43, 683-690.	1.0	5
645	Longitudinal follow up of a boy affected by Pol III-related leukodystrophy: a detailed phenotype description. BMC Medical Genetics, 2015, 16, 53.	2.1	5
646	Rho-kinase signaling controls nucleocytoplasmic shuttling of class IIa Histone Deacetylase (HDAC7) and transcriptional activation of orphan nuclear receptor NR4A1. Biochemical and Biophysical Research Communications, 2015, 459, 179-183.	1.0	5
647	Uniparental disomy of chromosome 1 unmasks recessive mutations of PPT1 in a boy with neuronal ceroid lipofuscinosis type 1. Brain and Development, 2017, 39, 182-183.	0.6	5
648	Keloids, Spontaneous or After Minor Skin Injury: Importance of Not Missing Bethlem Myopathy. Acta Dermato-Venereologica, 2017, 97, 297-298.	0.6	5

#	Article	IF	CITATIONS
649	A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1― written by pechmann and colleagues― European Journal of Paediatric Neurology, 2018, 22, 729-731.	0.7	5
650	Nuclear Factor Erythroid 2-Related Factor 2 Activation Might Mitigate Clinical Symptoms in Friedreich's Ataxia: Clues of an "Out-Brain Origin―of the Disease From a Family Study. Frontiers in Neuroscience, 2021, 15, 638810.	1.4	5
651	Altered cytoskeletal arrangement in induced pluripotent stem cells and motor neurons from patients with riboflavin transporter deficiency. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	5
652	Myocardial and Arrhythmic Spectrum of Neuromuscular Disorders in Children. Biomolecules, 2021, 11, 1578.	1.8	5
653	New Insights into the Neurodegeneration Mechanisms Underlying Riboflavin Transporter Deficiency (RTD): Involvement of Energy Dysmetabolism and Cytoskeletal Derangement. Biomedicines, 2022, 10, 1329.	1.4	5
654	Late onset scleroatonic familial myopathy (Ullrich disease): A study of two sibs. American Journal of Medical Genetics Part A, 1988, 31, 933-942.	2.4	4
655	Familial spastic paraplegia, axonal sensory-motor polyneuropathy and bulbar amyotrophy with facial dysmorphia: New cases of Troyer-like syndrome. European Journal of Paediatric Neurology, 1998, 2, 245-254.	0.7	4
656	Blood malignancies presenting with mutations at equivalent residues in RUNX1–2 suggest a common leukemogenic pathway. Leukemia and Lymphoma, 2017, 58, 2002-2004.	0.6	4
657	Somatic mosaicism represents an underestimated event underlying collagen 6-related disorders. European Journal of Paediatric Neurology, 2017, 21, 873-883.	0.7	4
658	A prospective natural history study of type 1 spinal muscular atrophy. Nature Reviews Neurology, 2018, 14, 197-198.	4.9	4
659	Response to "Autosomal recessive axonal neuropathy caused by HINT1 mutation: New association of a psychiatric disorder to the neurological phenotype― Neuromuscular Disorders, 2020, 30, 265-266.	0.3	4
660	Novel ACTA1 mutation causes late-presenting nemaline myopathy with unusual dark cores. Neuromuscular Disorders, 2021, 31, 139-148.	0.3	4
661	Artificial Intelligence for Dysarthria Assessment in Children With Ataxia: A Hierarchical Approach. IEEE Access, 2021, 9, 166720-166735.	2.6	4
662	Neurological and Neuroimaging Features of CYB5R3-Related Recessive Hereditary Methemoglobinemia Type II. Brain Sciences, 2022, 12, 182.	1.1	4
663	Reducing body myopathy and desmin storage in skeletal muscle: morphological and biochemical findings. Acta Neuropathologica, 1994, 87, 106-112.	3.9	4
664	"Atypical―Krabbe disease in two siblings harboring biallelic GALC mutations including a deep intronic variant. European Journal of Human Genetics, 2022, , .	1.4	4
665	Superior Cerebellar Atrophy: An Imaging Clue to Diagnose ITPR1-Related Disorders. International Journal of Molecular Sciences, 2022, 23, 6723.	1.8	4
666	Analysis of mutagenic activity in human urine after concentration on different resins and high-performance liquid chromatography. Toxicology Letters, 1989, 45, 241-249.	0.4	3

#	Article	IF	CITATIONS
667	Restriction in T-Cell Receptor Repertoire in a Patient Affected by Trichothiodystrophy and CD4+ Lymphopenia. Scandinavian Journal of Immunology, 2002, 56, 212-216.	1.3	3
668	De novoα-actin mutations in monozygotic twins. Clinical Genetics, 2005, 68, 91-92.	1.0	3
669	Cerebellar hypoplasia and brainstem thinning associated with severe white matter and basal ganglia abnormalities in a child with an mtDNA deletion. Journal of Inherited Metabolic Disease, 2011, 34, 1225-1227.	1.7	3
670	Defects of RNA metabolism in the pathogenesis of spinal muscular atrophy. Neurology, 2014, 82, 1298-1299.	1.5	3
671	Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy?. Neuromuscular Disorders, 2016, 26, 261-263.	0.3	3
672	Neuromyopathy with congenital cataracts and glaucoma: a distinct syndrome caused by POLG variants. European Journal of Human Genetics, 2018, 26, 367-373.	1.4	3
673	Primary muscle involvement in a 15â€yearâ€old girl with the recurrent homozygous c.362dupC variant in <i>FKBP14</i> . American Journal of Medical Genetics, Part A, 2019, 179, 317-321.	0.7	3
674	A wearable video-oculography based evaluation of saccades and respective clinical correlates in patients with early onset ataxia. Journal of Neuroscience Methods, 2020, 338, 108697.	1.3	3
675	Predictive fat mass equations for spinal muscular atrophy type I children: Development and internal validation. Clinical Nutrition, 2021, 40, 1578-1587.	2.3	3
676	Personalized profiles of antioxidant signaling pathway in patients with tuberculosis. Journal of Microbiology, Immunology and Infection, 2022, 55, 405-412.	1.5	3
677	Ageâ€related sensory neuropathy in patients with spinal muscular atrophy type 1. Muscle and Nerve, 2021, 64, 599-603.	1.0	3
678	Expanding the Clinical and Mutational Spectrum of the PLP1-Related Hypomyelination of Early Myelinated Structures (HEMS). Brain Sciences, 2021, 11, 93.	1.1	3
679	A novel homozygous variant in <scp> <i>COX5A</i> </scp> causes an attenuated phenotype with failure to thrive, lactic acidosis, hypoglycemia, and short stature. Clinical Genetics, 2022, 102, 56-60.	1.0	3
680	Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study. Acta Neuropathologica Communications, 2022, 10, 54.	2.4	3
681	Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain, 2022, 145, 3383-3390.	3.7	3
682	Benign congenital hypotonia with uniform type 1 fibers and aspecific ultrastructural changes in the muscle: a case with esophagus involvement. Italian Journal of Neurological Sciences, 1985, 6, 317-321.	0.1	2
683	Myotonic dystrophy and chromosome translocation segregating in the same family. Journal of Neurogenetics, 1987, 4, 47-56.	0.6	2
684	A new therapeutic approach for X-linked adrenoleukodystrophy. European Journal of Pediatrics, 1990, 149, 595-596.	1.3	2

#	Article	IF	CITATIONS
685	Clinical factors as predictors of survival in spinal muscular atrophy type I. Paediatrics and Child Health (United Kingdom), 2008, 18, S43-S47.	0.2	2
686	Pediatric reference intervals for muscle coenzyme Q10. Biomarkers, 2012, 17, 764-766.	0.9	2
687	SSADH deficiency in an adult. Neurology, 2015, 85, 842-843.	1.5	2
688	PIGQ-Related Glycophosphatidylinositol Deficiency Associated with Nonprogressive Congenital Ataxia. Cerebellum, 2022, 21, 525-530.	1.4	2
689	Body mass index in type 2 spinal muscular atrophy: a longitudinal study. European Journal of Pediatrics, 2022, , 1.	1.3	2
690	Genetic modifiers of upper limb function in Duchenne muscular dystrophy. Journal of Neurology, 2022, 269, 4884-4894.	1.8	2
691	Carnitine in lactic acidosis. Journal of Pediatrics, 1988, 112, 678.	0.9	1
692	Characterization of recessive RYR1 mutations in core myopathies. Human Molecular Genetics, 2007, 16, 1269-1269.	1.4	1
693	Mitochondrial DNA depletion syndromes: an update. Paediatrics and Child Health (United Kingdom), 2009, 19, S32-S37.	0.2	1
694	Mitochondrial DNA depletion syndrome presenting with ataxia and external ophthalmoplegia: Case report. Egyptian Journal of Medical Human Genetics, 2012, 13, 351-357.	0.5	1
695	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders, 2015, 25, S313.	0.3	1
696	Muscle imaging in fibrodysplasia ossificans progressiva: The neurologist's perspective. Neuromuscular Disorders, 2015, 25, 672-673.	0.3	1
697	Skin and Hair Disorders. , 2017, , 341-370.		1
698	Mitochondrial Neurodegenerative Disorders II: Ataxia, Dystonia and Leukodystrophies. , 2019, , 241-256.		1
699	An unusual case of late-infantile onset Krabbe disease with selective bilateralÂcorticospinal tract involvement, peripheral demyelinating neuropathy, and mild phenotype. Acta Neurologica Belgica, 2019, 119, 619-620.	0.5	1
700	Challenges and resources in adult life with Joubert syndrome: issues from an international classification of functioning (ICF) perspective. Disability and Rehabilitation, 2021, , 1-8.	0.9	1
701	Circadian Genes as Exploratory Biomarkers in DMD: Results From Both the mdx Mouse Model and Patients. Frontiers in Physiology, 2021, 12, 678974.	1.3	1
702	Clinico-Genetic, Imaging and Molecular Delineation of COQ8A-Ataxia: A Multicenter Study of 59 Patients. , 2020, 88, 251.		1

#	Article	IF	CITATIONS
703	Metabolic and Mitochondrial Ataxias. , 2003, , 231-252.		1
704	Ataxia in mitochondrial disorders. , 2001, , 548-561.		1
705	OXPHOS and mtDNA alterations in a family with spastic paraparesis. Acta Neurologica Scandinavica, 2000, 101, 255-258.	1.0	1
706	Skin and Hair Disorders. , 2010, , 197-217.		1
707	Modeling PCDH19-CE: From 2D Stem Cell Model to 3D Brain Organoids. International Journal of Molecular Sciences, 2022, 23, 3506.	1.8	1
708	Sacral evoked reflex in children. Neurourology and Urodynamics, 1985, 4, 149-150.	0.8	0
709	Acute quadriplegic myopathy in a 16-month-old child. Paediatric Anaesthesia, 2005, 15, 611-615.	0.6	0
710	Dystrophic myopathies of early childhood onset (congenital muscular dystrophies). , 0, , 257-281.		0
711	Merosin deficient congenital muscular dystrophy: Clinical, neuroimaging and immunohistochemical study of 8 Egyptian pediatric patients. Journal of Genetic Engineering and Biotechnology, 2013, 11, 61-68.	1.5	0
712	Congenital myopathies. Neurology, 2015, 84, 15-16.	1.5	0
713	Response to: Mitochondrial neuropathy affects peripheral and cranial nerves and is primary or secondary or both. Neuromuscular Disorders, 2016, 26, 549.	0.3	0
714	Response to Jardim and colleagues regarding comments on â€~Natural history of a cohort of <i><scp>ABCD</scp>1</i> variant female carriers'. European Journal of Neurology, 2019, 26, e77.	1.7	0
715	Neonatal Hypotonia. , 2019, , 223-233.		0
716	Long-Term Outcome of LVAD in Duchenne Population with End Stage Cardiomyopathy. Journal of Heart and Lung Transplantation, 2020, 39, S219-S220.	0.3	0
717	Aicardi–Coutières Syndrome Type 2: A Report on Two Cases with Different Phenotypes Caused by RNASEH2B Gene Mutations. Journal of Pediatric Neurology, 2020, 18, 206-209.	0.0	0
718	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 479-488.	0.3	0
719	Broadening the spectrum phenotype of TBCE-related neuron neurodegeneration. Brain and Development, 2021, 43, 939-944.	0.6	0

The Skin as a Clue for the Diagnosis of Inherited Metabolic Disorders. , 2008, , 1023-1042.

0

#	Article	IF	CITATIONS
721	Mitochondria fingerprint longevity in iPSCs. Oncotarget, 2015, 6, 5475-5476.	0.8	0
722	A case of spastic paraplegia type 11 mimicking a GM2-gangliosidosis. Neurological Sciences, 2022, 43, 2849-2852.	0.9	0
723	Toward the inÂvitro understanding of iPSC nucleoskeletal and cytoskeletal biology, and their relevance for organoid development. , 2022, , 137-150.		0
724	Cerebellar Agenesis and Bilateral Polimicrogyria Associated with Rare Variants of CUB and Sushi Multiple Domains 1 Gene (CSMD1): A Longitudinal Neuropsychological and Neuroradiological Case Study. International Journal of Environmental Research and Public Health, 2022, 19, 1224.	1.2	0
725	Novel <i>SEPSECS</i> Pathogenic Variants Featuring Unusual Phenotype of Complex Movement Disorder With Thin Corpus Callosum. Neurology: Genetics, 2022, 8, e661.	0.9	0
726	Response to: Phenotypic heterogeneity of Leigh syndrome due to <i>NDUFA12</i> variants is multicausal. Human Mutation, 2022, 43, 99-100.	1.1	0
727	A clinical and epidemiological prevalence study on Friedreich's Ataxia in Latium, Italy Neuroepidemiology, 0, , .	1.1	0